Curriculum Vitae



Name: Zhe-Sheng (Jason) Chen, MD. Ph. D.

Place of Birth: Guangdong Province, P. R. China.

Office Address: 8000 Utopia Parkway, Queens, New York, NY 11439 USA

Tel: 1-7189901432; Fax: 1-7189901877, E-mail: Chenz@stjohns.edu or chen15245@yahoo.com

**Education:**

1993-1998 Ph.D. degree (**Cancer Pharmacology**) from Graduate School of Medical and Dental Sciences, Kagoshima University, Japan

1985-1988 Masters degree (**Toxicology**) from Sun Yat-Sen University of Medical Sciences, P. R. China.

1980-1985 M.D. degree from Guangdong Medical and Pharmaceutical College, P. R. China.

**Research and Professional Experience**:

2012-present Full Professor with tenure, St. John’s University.

2010-2012 Associate Professor with tenure, St. John’s University.

2008-2012 Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy

 and Health Sciences, St. John’s University.

2004-2008 Assistant Professor, Department of Pharmaceutical Sciences, College of Pharmacy

 and Health Sciences, St. John’s University.

2002-2004 Research Associate at Fox Chase Cancer Center with Dr. Gary D. Kruh

2000-2002 Postdoctoral Associate at Fox Chase Cancer Center with Dr. Gary D. Kruh.

1998-2000 Research Fellow of Japan Society for the Promotion of Sciences, with Professor Shin-ichi Akiyama. 8-35-1 Sakuragaoka Kagoshima 890-0085 Japan.

1990-1993 Associate Director, Department of Environmental Toxicology, Center for Diseases

Control and Prevention, Guangdong, China

1988-1990 Attending Doctor, Center for Diseases Control and Prevention, Guangdong, China

Adjunct Positions:

2016-present Henan Provincial People’s Hospital, Zhengzhou, China

2015-present Weifang Medical University, Weifang, China

2015-present Qingdao Agriculture University, Qingdao, China

2012-present Guangzhou Medical University, Guangzhou, China

2011-present Jinan University, Guangzhou, China

2009-present Central South University, Changsha, China

2009-present Sun Yat-Sen University Cancer Center, Guangzhou, China

2009-present Guangdong Pharmaceutical University

2007-present University of Louisiana College of Pharmacy at Monroe, USA

**Professional Activities**:

 1. Professional affiliations

1). American Association of Colleges of Pharmacy (AACP, Active Member), 2004-present.

2). American Association for Cancer Research (AACR), associate member, 1997-2003;

 active member, 2003-present.

3). Founding President of US-China Science and Education Association

 <http://www.ucsea.net/index.html> (美中科学与教育学会创会会长).

4). Member of Asian Council of Science Editors, 2015-present.

 2. Grant Review Activities

 1). Ad hoc reviewer, out of State Grant Reviewer for The Board of Regents Support Fund

 Research and Development (R&D) Program, 2008-

 2). Ad hoc reviewer, The Genesis Oncology Trust, New Zealand, 2009-

 3). Ad hoc reviewer, NIH, NCI Special Emphasis Review Panel, OmniBus SEP-10, USA, 2016-

 4). Ad hoc reviewer, National Science Centre, Poland, 2013-

 5). Ad hoc reviewer, The Government of the Hong Kong Special Administrative
 Region(HKSAR) Grant, Hong Kong, China, 2014-

 6). Ad hoc reviewer, National Natural Science Foundation, China, 2014.

 7). Ad hoc reviewer, the Hungarian Scientific Research Fund (OTKA), Hungary, 2014-

 8). Ad hoc reviewer, the Netherlands Organisation for Scientific Research (NWO), 2016-

 9). Ad hoc reviewer, the Kentucky Science & Engineering Foundation (KSEF), 2016-

 3. Chair of scientific meetings

1. Co-Chair of 12th World Congress on Advances in Oncology and 10th International Symposium on Molecular Medicine, 11-13 October, 2007, Creta Maris, Hersonissos, Crete, Greece
2. Co-Chair of the 4th North American ABC workshop, 4-5 October, 2007, Frederick. Maryland.
3. Co-Chair of the 6th North American ABC workshop, 24-25 Sept., 2009, Frederick. Maryland.
4. Co-Chair of the 9th North American ABC workshop, 27-28 Sept., 2012, Frederick. Maryland.
5. Co-Chair of the 10th North American ABC workshop,19-20 Sept., 2013, Frederick. Maryland.
6. Co-Chair of the BIT’s 7th World Cancer Congress, 16-18 May, 2014, Nanjing, China

4. Editorial leadership positions:

1) Editor-in-Chief:I: *Journal of Cancer Research Updates* (JCRU)

 II: *Journal of New Developments in Chemistry* (JNDC)

2) Editor: *African Journal of Pharmacy and Pharmacology* (AJPP)

3) Regional Editor: *Recent Patents on Anticancer Drug Discovery* (RPADD)

4) Guest-Editor: I: *Current Pharmaceutical Biotechnology*

 II: *Cancers*

 III: *Journal of International Medical Research*

5) Associate Editor: I: *Journal of Analytical Oncology*,

 II: *Journal of Cancer Metastasis and Treatment* (JCMT)

5. Senior Editorial Advisor, Academic Editor, and Editorial Board Member of the following journals:

1) *American Journal of Cancer Research* (AJCR) (<http://www.ajcr.us/EditorialBoard.html>)

 2) *The Open Breast Cancer Journal* ([www.bentham.org/open/tobcanj](http://www.bentham.org/open/tobcanj#_blank))

3) *The Open Drug Resistance Journal* ([*http://www.bentham.org/open/todrj*](http://www.bentham.org/open/todrj#_blank))

4) *Chinese Journal of Cancer\* (AiZheng) (*[*http://www.cjcsysu.cn/*](http://www.cjcsysu.cn/) *)*

5) *Drug Discoveries & Therapeutics* (<http://www.ddtjournal.com/> )

6) *Journal of Chinese Clinical Medicine (*[*http://www.cjmed.net/*](http://www.cjmed.net/) *)*

7)  *Recent Patents on Anticancer Drug Discovery (*[*http://www.bentham.org/pra/EBM.htm*](http://www.bentham.org/pra/EBM.htm) *)*

8) *World Journal of Clinical Oncology (*[*http://www.biomedcentral.com/content/pdf*](http://www.biomedcentral.com/content/pdf) *)*

9) *Bioinorganic Chemistry and Applications\* (*[*http://www.hindawi.com/journals/bca/*](http://www.hindawi.com/journals/bca/) *)*

10) *Metal Based Drugs\* (*[*http://www.hindawi.com/journals/mbd/editors.html*](http://www.hindawi.com/journals/mbd/editors.html) *)*

11) *Pharmaceutica Analytica Acta\*(*[*http://www.omicsonline.org/EditorialboardPAA.php#*](http://www.omicsonline.org/EditorialboardPAA.php) *)*

12) *Journal of Carcinogenesis & Mutagenesis (*[*http://www.omicsonline.org/EditorialboardJCM.php*](http://www.omicsonline.org/EditorialboardJCM.php)*)*

13) *World Journal of Pharmacology (*[*http://www.wjgnet.com/2218-6263/about.htm*](http://www.wjgnet.com/2218-6263/about.htm) *)*

14) *Acta Pharmaceutica Sinica B*

15) *Journal of Pharmacy and Nutrition Sciences\**

16) *Journal of New Developments in Chemistry\**

17) *International Journal of Clinical Pharmacology & Toxicology (IJCPT)*

18) *The Open Leukemia Journal* (<http://www.bentham.org/open/toleukemiaj/EBM.htm> )

19) [*Journal of Molecular Pharmaceutics & Organic Process Research*](https://owa.stjohns.edu/owa/redir.aspx?C=6eebcb0099b940dea82b57f18a9ded69&URL=http%3a%2f%2fwww.esciencecentral.org%2fjournals%2fmolecular-pharmaceutics-organic-process-research.php)\*

20) *Journal of Developing Drugs*\* *(*[*http://www.omicsgroup.org/journals/*](http://www.omicsgroup.org/journals/) *)*

21) *VRI Cell Signaling* (<http://vedicjournals.com/index.php/CS>)

22) *International Journal of Cancer Research & Diagnostics (IJCRD)*

23) *Journal of Scientific Research and Reports* \*

24) *Pharmacologia* (<http://pharmacologia.com>)

*\** Serve as an academic editor to handle the assignment of article review processing.

10. Peer Journal Review Activities (180 journals)

Ad hoc Reviewer: 1.***Cancer Research****,* 2*. Cancer Letters,* 3. *Journal of Pharmacy and Pharmacology,* 4. *Cancer Chemotherapy and Pharmacology,* 5. *Cancer Science,* 6. *Drug Metabolism and Disposition,* 7. *Acta Pharmacologica Sinica,* 8. *Cell Biology and Toxicology,* 9. *Molecular Cancer Therapeutics,* 10. *Chinese Journal of Cancer (AiZheng),* 11. *European Journal of Cancer,* 12. *Chemotherapy,* 13. *Leukemia Research,* 14. *The Open Leukemia Journal,* 15. *International Journal of Cancer,* 16. *The Open Breast Cancer Journal,* 17. *Biochemical Pharmacology,* 18. *The Open Drug Resistance Journal,* 19. *Drug Discoveries & Therapeutics,* 20. *Current Cancer Drug Targets,* 21. *Letters in Drug Design & Discovery,* 22. *Biomarkers,* 23. *Molecular Cancer,* 24. *Recent Patents on Anti-Cancer Drug Discovery,* 25. *Journal of Chinese Clinical Medicine,* 26. *Molecular Pharmaceutics,* 27. *Bioorganic & Medicinal Chemistry,* 28. *Current Pharmaceutical Biotechnology,* 29. *Acta Biochimica et Biophysica Sinica,* 30. *World Journal of Clinical Oncology,* 31. *Cancer,* 32. *Journal of Translational Medicine,* 33. *Frontiers in Bioscience,* 34. *Pharmaceutica Analytica Acta,* 35. *Journal of Carcinogenesis & Mutagenesis,* 36. *Journal of Gastroenterology and Hepatology,* 37. *Expert Opinion on Therapeutic Patents,* 38. *Human and Experimental Toxicology,* 39. *Mini-Review in Medicinal Chemistry,* 40.***Journal of Biological Chemistry****,* 41. *Journal of Cellular and Molecular Medicine,* 42 *Journal of Pharmacy and Bioallied Sciences,* 43 *Pharmacogenetics and Genomics, 44.The Drugs of the Future,* 45.*PLoS One,* 46.*Current Medicinal Chemistry,* 47.*Molecular Medicine Reports,* 48.*Xenobiotica, Drug Metabolism and Drug Interactions,* 49.*Cancer Cell International,* 50. *Marine Drugs,* 51.*Lung Cancer,* 52. *BBA-Biomembranes,* 53.*AIDS Research and Therapy,* 54.*Expert Opinion on Investigational Drugs,* 55.*Journal of Medical Genetics and Genomics,* 56. *Medical Science Monitor,* 57. *Clinical Pharmacology and Biopharmaceutics,* 58. *Toxicology Mechanisms and Methods,* 59.*Journal of Proteome Research,* 60. *Future Oncology,* 61. *Analytical letters,* 62. *Journal of Molecular Modeling,* 63. *Chemical Neuroscience,* 64.*Molecular Therapy,* 65.*Molecular and Cellular Proteomics,* 66.*Pharmacogenomics,* 67.*ChemMedChem,* 68.*European Journal of Pharmaceutical Science,* 69. *African Journal of Pharmacy and Pharmacology,* 70.*Biochemistry & Pharmacology,* 71. *Clinical Cancer Drugs,* 72.*Drug and Chemical Toxicology,* 73.*Acta Oto-Laryngologica,* 74.*Bioscience Trends,* 75.*Journal of Pharmacologic and Toxicologic Methods,* 76.*Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry,* 77*. Antibiotics,* 78*.Virology Journal,* 79. *Drug Discover Today,* 80.*Molecular and Cellular Biochemistry,* 81. *Biochemistry and Cell Biology,* 82. *African Journal of Microbiology Research,* 83. *Journal of Biological Regulators & Homeostatic Agents,* 84. ***Leukemia****,* 85. *Molecules,* 86. *Expert Opinion on Drug Metabolism and Toxicology,* 87.*Medicinal Research Reviews,* 88. *International Journal of Nanomaterials,* 89.*The Journal of Xenobiotics,* 90. *Chemistry Communications,* 91. *World Journal of Obstetrics and Gynecology,* 92.***ACS Nano****,* 93.*NanoMedicine: Nanotechnology, Biology and Medicine,* 94.*Journal of Materials Chemistry B,* 95. *Journal of Surgical Oncology,* 96.*Oxidative medicine and Cellular Longevity,* 97.*Cancer Gene Therapy,* 98.*Cutaneous and Ocular Toxicology,* 99. *Pharmacoepidemiology and Drug Safety,* 100.*Journal of Nanoparticle Research,* 101, *Toxicology Research,* 102*. Journal of Experimental & Clinical Cancer Research,* 103.*Breast Cancer Research,* 104.***Oncogene****,* 105.*World Journal of Gastroenterology,* 106.***Nature Communications****,* 107.*Medicinal Chemistry Communication,* 108.*Drug Deliver,* 109.*Chemico-Biological Interactions,* 110.*Biological Research,* 111.*Canadian Journal of Physiology and Pharmacology,* 112. *Molecular BioSystems,* 113. *International Journal of Molecular Sciences,* 114.*Oncotarget,* 115.*Journal of Endocrinology,* 116.*Journal of Proteomics,* 117.*International Journal of Pharmaceutics,* 118.*Biomed Research International,* 119. *RSC Advances,* 120. *Climacteric,* 121.*Biomaterials,* 122.*Cancer Biology & Medicine,* 123.*World Journal of Surgical Oncology,* 124. *Experimental and Molecular Pathology,* 125*. Lipids,* 126*. Leukemia Research and Treatment,*127. *Tumor Biology,* 128*. Nutrients,* 129*. Future Medicinal Chemistry,* 130*.* *Annals of Surgical Oncology,* 131. *Journal of the Neurological Sciences,* 132. *Journal of Inorganic Biochemistry,* 133. *Journal of Membrane Biology,* 134. *Bioorganic & Medicinal Chemistry,* 135*. British Journal of Pharmacology*. 136. *Cellular Physiology and Biochemistry,* 137. *Expert Review of Anticancer Therapy,* 138*. Drug development and Industrial Pharmacy,*139*.* ***Stem Cells****,(IF: 7.1)* 140. *Oncology Letters,* 141*. Ethnopharmacology (IF: 2.94),* 142.***Biomaterials*** *(IF: 8.3),* 143. *Computational Biology and Chemistry (IF: 1.5),* 144. *Oncology Reports (IF: 2.2),* 145. *Toxicology in Vitro.* 146*. International Journal of Oncology (IF: 2.6),* 147*. BioMed Research International (IF: 2.76).*148, *Journal of Cellular Biochemistry (IF: 3.4).*149. *Anticancer Drugs,* 150. *International Journal of Nanomedicine (IF: 4.20),* 151, *European Journal of Pharmaceutics and Biopharmaceutics (IF: 4.245),* 152, *Journal of Infection and Public Health.* 153*, Organic & Biomolecular Chemistry,* 154*, Therapeutic Advances in Medical Oncology,* 155. *Evidence-Based Complementary and Alternative Medicine,* 156. *Experimental Cell Research,* 157. *Phytomedicine,* 158. *Pharmacological Research,* 159. *Journal of Industrial and Engineering Chemistry (IF: 3.5).*160. *Toxicology Letters* (IF: 3.3*).* 161. *Lung* (IF: 2.27). 162. *Journal of Biomedicine Nanotechnology* (IF: 5.34). 163. *Xenobiotica* (IF: 2.1). 164. *Computational and Mathematical Methods in Medicine* (IF: 0.76). 165. *Cancer Investigation*(IF: 2.18). 166. *Arabian Journal of Chemistry* (IF:3.73), 167. *Molecular Cancer Research* (IF:4.38), 168. *International Journal of Biological Sciences* (IF: 4.51), 169. *Data in Brief*, 170. *Turkish Journal of Gastroenterology* (IF: 0.78). 171. *Chemical Physics Letters* (IF:1.9). 172. *International Journal of Molecular Medicine* (IF: 2.1). 173. *Current Drug Metabolism* (IF: 2.96), 174. *Journal of Gynecologic Oncology* (IF: 2.5). 175. *Cancer Genetics* (IF: 2.99), 176, BMC Anesthesiology (IF:1.375), 177. *Scientific Reports* (IF: 5.6). 178. *Current Pharmaceutical Design* (IF: 3.45). 179. *Drug Delivery* (IF: 2.558). 180. European Journal of Medicinal Chemistry (IF:3.447).

**Teaching and Supervision experience:**

2004-present Lecturer of “Drugs and Diseases/Oncology”(PHR5109), “Drugs and Diseases/GI&GU” (PHR5107), “Introduction to Pharmacology” (PHS 3509), “Biopharmaceutical Chemistry” (PHS 2201), “Clinical Pharmacology”, (PHS 221) “Advanced Pharmacology” (PHS 202), “Pharmacology of Anticancer Drugs” (PHM 240) “Principle of Pharmacology II” (PHS103) and Pharmacology Journal Club (PHM232) at St. John’s University.

2004-present Supervisor of Ph. D, Masters students, postdoctoral fellows and visiting scholars at St. John’s University.

1995-1998 Teaching Assistant, Oncology for medical students at Kagoshima University

1995-2000 Supervisor of 4 medical doctors from Department of Surgery, Faculty of Medicine,

 Kagoshima University

**Postdoctoral fellows or visiting scholars (2006~):**

1. Dr. Xiao-Cong Huang (a visiting scholar from Shantou University), April ~ Aug, 2006.

2. Dr. Zhi Shi (a postdoctoral fellow from Sun Yat-Sen University),

April, 2006~ April, 2007; currently a professor at Jinan University.

3. Dr. Si-Rong Wang (a visiting scholar from Guangzhou University of Traditional

Chinese Medicine), Aug, 2007 ~ Aug, 2009.

4. Mr. Jefferson Lee (a visiting scholar from University of Bath, England), Aug, 2008 ~ June, 2009.

5. Dr. Ye-Hong Kuang (a visiting scholar from Central South University Medical School), Sept, 2008 ~

 May, 2009; currently an associate professor and a clinical doctor at Xiangya Hospital.

6. Dr. Wen Deng (postdoctoral fellow from Zhaoqin People’s Hospital, Guangdong, China),

Aug. 2009~, currently a clinical doctor in New York.

7. Dr. Chun-Ling Dai (postdoctoral fellow from Sun Yat-Sen University Cancer Center),

Sept. 2009~Aug. 2011. Currently a postdoctoral fellow in a research institute in Staten Island, New York.

8. Dr. Peirong Ding (visiting scholar from Sun Yat-Sen University Cancer Center, China),

Aug. 2009~June 2010. Currently an associate professor and a clinical doctor in Sun Yat-Sen University Cancer Center

9. Dr. Xin An (visiting scholar from Sun Yat-Sen University Cancer Center, China), Sept.

2009~June 2010. Currently a clinical doctor in Sun Yat-Sen University Cancer Center.

10. Ms. Shirley Lu (visiting scholar from Southern Medical University, China), July,

2010~Aug. 2010. Currently a graduate student in Southern Medical University.

11.Dr. Junjiang Chen (visiting scholar from Guangdong Pharmaceutical University), Sept.

2010 ~ Dec. 2011. Currently a Ph. D student in Hongkong Chinese University.

12. Dr. Xiangqian Li (visiting scholar from Huaiying Institute of Technology), Dec.

2010~May, 2011. Currently a professor in Huaiyin Institute of Technology.

13. Dr. Yueli Sun (visiting scholar from Sun Yat-Sen University Cancer Center), Jan. 2011~Jan, 2012.

 Currently a doctor at Sun-Yat-Sen University Cancer Center.

14. Dr. Danwen Yang (visiting scholar from Central South University, China), Sept. 2011~May, 2014.

 Currently a resident of Physician in USA.

15. Dr. Deshen Wang (visiting scholar from Sun Yat-Sen University Cancer Center, China), Nov.

 2012~Nov. 2013. Currently a clinical doctor at Sun-Yat-Sen University Cancer Center.

16. Dr. Hui Zhang (visting scholar from Sun Yat-Sen University Cancer Center, China), Dec.

 2012~Dec. 2013. Curently a clinical doctor at Shandong Tumor Hospital, China.

17. Dr. Liuya Wei (visiting scholar from Weifang Medical College, China), Nov. 2013-Nov. 2014, Curently an Associate Professor at Weifang Medical College, China.

18. Dr. Zehua Bian (postdoc fellow from South China Medical University, China), Feb, 2014~

19. Dr. Hua Sui (visiting scholar from Shanghai Traditional Chinese University, China), April, 2014-Aug. 2014, Curently a clinical doctor at Shuguan Hospital, Shanghai, China.

20. Dr. Meina Xie (visting scholar from Weifang Medical College, China), April, 2015-Jan. 2016. Curently an Associate Professor at Weifang Medical College, China.

21. Dr. Bin Zhou (visiting scholar from Nanchan Technology and Normal University, China), July, 2015~

22. Ms. Chaoyun Cai (visiting scholar from Sun-Yat-Sen University, China), Oct, 2015~

23. Dr. Jun Li (visiting scholar from Zhongnan Hospital, Wuhan, China, April, 2016~

**Ph. D students (2004~):**

1. Mr. Xing-Xiang Peng (Dec. 04-Dec. 2007, a research fellow at New York University, New York)

2. Ms. Ioana Abraham (Sept. 04-Dec. 2011, a Postdoctoral fellow at Mount Sinai Medical

 Center, New York)

3. Mr. Amit Tiwari (Sept. 08-June 2011, an assistant professor at University of Toledo)

4. Mr. Saurabh Vispute (Sept. 09-Dec.2015, a Ph. D candidate, co-mentoring with Dr. Ashby)

5. Mr. Kamlesh Sodani (Jan. 10-June 13, a postdoc at The Feinstein Institute for Medical Research at North Shore-LIJ)

6. Mr. Atish Patel (Jan. 11-June 14, currently a postdoc at NCI, NIH)

7. Mr. Priyank Kumar (July 11-June 14, currently an assistant professor at Touro College of Pharmacy)

8. Mr. Rishil J. Kathawala (Sept. 12-June 14, currently a postdoc at Stanford University)

9. Mr. Nagaraju Anreddy (Jan. 12-May, 2015, co-mentoring with Dr. Wurpel, a postdoc at Virginia University from June, 2015)

10.Mr. Yunkai Zhang (Sept. 12~, a Ph. D candidate)

11.Ms. Guannan Zhang (Sept. 12~, a Ph. D candidate, co-mentoring with Dr. Wurpel)

12.Mr. Yijun (Alex) Wang (Jan 14~May, 16), a postdoc at Pittsburg University.

13.Ms. Anna Maria Barbuti (Sept, 14~ a Ph. D. candidate)

14. Mr. Albert De Vera (Jan. 2015~ a Ph. D candidate, co-mentoring with Dr. Reznik)

15. Mr. Pranav Gupta (Sept. 15~ a Ph. D. Candidate)

**Master students (2004~):**

1. Ms. Moss Wu (Sept, 04-Dec. 06, Staff at Protech Pharmaservices Corporation, Taipei)

2. Ms. Smitaben Parmar (Sept, 04-April. 07, a pharmacist in Palm Beach, Fl, USA)

3. Ms. Ying Zhou (Sept, 04-May 07, a research associate at University of Wisconsin Medical School)

4. Mr. Amit Tiwari (Sept, 06-July, 08, and a Ph. D student from Aug. 2008, graduated in June 2011)

5. Ms. Tong Shen (Sept, 06-April 09, and a staff at A & Z Pharmaceutics, Long Island)

6. Mr. Kamlesh Sodani (Sept., 07-Dec. 09, and a Ph. D student from Jan. 2010)

7. Ms. Selina Wang (a Master student from 2008, transferred to business school of St. John’s from 09’)

8. Mr. Atish Patel (Sept. 08-Dec.10, co-mentor with Dr. Stephani, a Ph. D student in the lab from

Jan. 2011, graduated from July 2014)

9. Ms. Zhijie Xiao (Jan. 10-May, 12, a Ph. D student at Hong Kong University from Sept. 12)

10.Mr. Rishil J. Kathawala (a Master St. from Sept. 2010, co-mentoring with Dr. Ashby, a Ph. D student at the lab from Sept. 12, graduated in Aug. 2014)

11.Mr. Yijun (Alex) Wang (a Master Student, Sept. 2011-Dec. 2013, a Ph.D. student from Jan. 2014 )

12.Mr. Pranav Gupta (a Master student, from Sept. 2013-May, 2015, a Ph.D. student from Sept. 2015)

13.Ms. Xiaoyu Zhang (a Master student, from Sept. 2014)

**Undergraduate students and Pharm D students (2004~)**

1. Mr. Yubo Sun ((Pharm. D student, graduated in 2010)
2. Ms. Christine Chim (Pharm. D student, graduated in 2011)
3. Mr. Yining Shao (Pharm. D student, will graduate in 2014) summer of 2011
4. Mr. Kevin Chen (Biophysics student, graduated in 2011, became a Medical student at

 UMDNJ) AACR undergraduate student travel award （2009-2011）

1. Mr. Chung Lee (Pharm. D student, graduated in 2011)
2. Mr. Daan Chen (Pharm. D student, graduated in 2014) summer of 2011

7. Mr. Lunbao Huang (Pharm. D student, graduated in 2013) summer of 2012

 8. Ms. Lina Lin (Pharm. D student, will graduate in 2017) summer of 2012

 9. Ms. Jieun Jung (Pharm. D student, will graduate in 2017) summer of 2012

 10. Ms. Peiqi Yang (B.S. Integrated Neuroscience - Harpur College of Arts and Science

State University of New York at Binghamton, class of 2015) summer of 2013

11. Mr. Richard Chung (Pharm. D student, will graduate in 2017) summer of 2013

12. Mr. Tim Ho (Pharm. D. student, will graduate in 2018) summer of 2015~

**High school students (2004~)**

1. Ms. Alby Jacob (Brox Sci High) (graduated in 2007, and as a Pharm D student at Northeastern University) (2005-2006 at the lab)
2. Mr. Yining Shao (Long Island High, graduated in 2008, and as a Pharm D student

at St. John’s University from 2008) (2007 at the lab)

1. Ms. Mimi Chen (Montgomery High) (graduated in 2009, and as a Pharm D student at

Rutgers University in New Jersey) (2007-2008 at the lab)

1. Ms. Angel Chen (Stuyvesant High) (graduated in 2009, and as a pre-med student at

**Columbia** University in New York) (2008-2009 at the lab)

1. Ms. Miranda Y. Mu (Stuyvesant High) graduated in 2009, and as a student at

**Wellesley** College (2008 at the lab)

1. Ms. Annie Zang (Stuyvesant High) graduated in 2010, and as a BS-MD student at

University of Miami (2007-2009 at my lab)

1. Mr. Timothy Hall (Great Neck South High School) will graduate in 2012. (2009 at the

lab) and as a Pharm D student at St. John’s University since 2012.

1. Mr. Yuxin Zhu (Jericho High School) graduated in 2011, and as a student at **University**

**of California, Berkeley** campus (2010~2011 at the lab, Intel talent award semi-final)

1. Mr. Kelvin Jiayu Zheng (Stuyvesant High) graduated in 2012，as a student at Case Western Reserved University. (2010 at the lab)
2. Ms. Yang-Lu Chen (Montgomery High), graduated in 2013, a student at **Princeton** University (2011 at the lab)
3. Mr. Haitian Liu (Brox Sci High), will graduate in 2013, a Pharm D student at St. John’s University (2012 at the lab)
4. Mr. Keyan Vakil (Jericho High School) graduated in 2014 (2013 at the lab).
5. Mr. Kanav Gupta(Jericho High School) graduated in 2014 (2013 at the lab).
6. Ms. Eugenie Chen (Farmington High School, Connecticut) graduated in 2015 (2013 at the lab)
7. Mr. Andrew Huang ( Newark High school, New Jersey) graduated in 2015 a student at **Rice** University (2014 at the lab)
8. Ms. Rui Si (Brox Sci High) will graduate in 2016 (2014 in the lab)
9. Ms. Fanyi Zeng (Guangzhou Zhixin High school), graduated in 2015 a student at **Wake Forest** University (2014 in the lab).
10. Ms. Jessalyn Li (William A. Shine Great Neck South HighSchool, Great Neck, New York) will graduate in 2016 (2014 in the lab).
11. Ms. Megan Xu (Great Neck North High School) will graduate in 2017 (2015 in the lab).
12. Ms. Kimberly Lu (Great Neck North High School) will graduate in 2017 (2015 in the lab).

**Awards:**

1994-1995 Sasakawa Health Science Foundation, Japan.

1995-1998 NAGASHIMA Culture Foundation Student Fellowship, Japan.

1997 Excellent Medical Student Prize, YASUDA Medical Research Foundation, Japan.

1997-1998 KOHNAN Asia International Student Fellowship, Japan.

1998 Young Investigators' award in 5th Hong Kong International Cancer Congress.

1998-2000 Research Fellowship of Japan Society for the Promotion of Science

2000-2004 The Japan Research Foundation for Clinical Pharmacology Award

 (for overseas research)

2001-2004 The W. J. Avery Fellowship from Fox Chase Cancer Center

1. Sixth Annual Postdoctoral Research Conference award, Fox Chase Cancer Center

2003 AACR-Ortho Biothech, Inc. Scholar-In-Training award, the 94th Annual AACR Meeting

2006 Summer Research Support from College of Pharmacy and Allied Health Professions

2007 Summer Research Support from College of Pharmacy and Allied Health Professions

2007 Faculty Recognition Award of St. John’s University

2008 Summer Research Support from College of Pharmacy and Allied Health Professions

2008 Faculty Recognition Award of St. John’s University

2009 Summer Research Support from College of Pharmacy and Allied Health Professions

2010 Faculty Recognition Award of St. John’s University

2011 Special Recognition Award of St. John’s University

2011 Faculty Recognition Award of St. John’s University

2012 Faculty Recognition Award of St. John’s University

2013 Summer Research Support from College of Pharmacy and Health Sciences

2013 Faculty Recognition Award of St. John’s University

2014 Faculty Recognition Award of St. John’s University

2015 Faculty Recognition Award of St. John’s University

2016 Outstanding Achievement Medal of St. John’s University

**Research Grant:**

1. Sasakawa Health Science Foundation, Japan 1994~96
2. "Grant-in-Aid for Scientific Research" from Japan Society for the

Promotion of Science 1998-00

1. St. John's University’s start-up funding 2004-09
2. Research Seed Grant from St. John’s University 2007-08
3. Research Seed Grant from St. John’s University 2008-09
4. Research Seed Grant from St. John’s University 2009-10
5. Research Support from Primary Care Medicine Associates PC 2009-17
6. Research Support from RayBiotech. Co 2009-14
7. NIH R15 Ovarian Cancer and MRP7 (PI) 2010-13
8. Biomarker Discovery Research Pilot Grants 2010-12
9. Research Support from New York Chinese Physician Association 2011-18
10. Research Support from NOF 2011-14
11. Research Seed Grant from St. John’s University 2012-13
12. Research Seed Grant from St. John’s University 2013-14
13. Research Seed Grant from St. John’s University 2015-16
14. NIH R15 Nanowaveguide Illuminated Fluorescence 2015-18

Spectroscopy for Studying Membrane Protein Dynamics (Co-PI)

1. Research support from Flushing OB/GYN, PC 2016-18

**Major Research Interests:**

Our primary goal is to develop more effective chemotherapeutic agents for cancer patients. Multidrug resistance (MDR) represents a major obstacle to the treatment of cancer, and understanding the resistance mechanisms and knowing how to reverse the resistance hold the promise of providing insights that may lead to improvements in the use of currently available anticancer drugs.

Our laboratory is interested in the molecular and cellular pharmacology of anticancer drugs, such as drug resistance mechanisms and reversal of resistance study and new drug development. A promise of our research program is that progress in the chemotherapy of cancer will depend on rational combination of agents that reduce the function of plasma membrane transporters such as P-gp, ABCG2 and MRPs, and to enhance the actions of cytotoxic drugs. In collaboration with many researchers in USA, China, Japan, Canada, Australia and Egypt, studies in our laboratory focus on screening and identifying new inhibitors of ABC transporters by *in vitro* membrane vesicles transport assay system and cell based assay systems. Another research direction is to study the role of ABC transporters family on the detoxification of chemicals (including carcinogens and mutagens) using knock out mouse models. In addition, I have a strong scientific writing and communication skills (grants and publications) as well as am active in public service with global and local impact.

**Patent(s):**

1. 成昌梅;杨永冲;常智杰;陈哲生;张峰;王冬春;陆爱军, N-苯基二氯乙酰胺及衍生物及其制备方法和应用, Chinese patent, 200910086132, June, 2009.

2. Zhe-Sheng Chen, Zhi Shi, Charles R. Ashby Jr.: "Use of phosphodiesterase inhibitors for treating multidrug resistance” U.S. Patent US 2012/0252816 A1 Oct. 4., 2012.

3. Zhe-Sheng Chen, Hui Zhang, Atish Patel: “BTK Inhibition combinations and multidrug resistance” U.S. Parent US 2015, In Press.

4. 徐进宜, 徐盛涛, 李达翃, 王诚倩, 姚鸿, 裴玲玲, 陈哲生, 张运闿, 张恒源, 张晨曦. 冬凌草甲素14-0-取代氮芥衍生物制备方法及用途，CN104003998A, Chinese patent, 2015.

**List of Publications**

***Publications* (Summary)**

Edited Books/Special Issues 4

Book Chapters 7

Refereed Journals 177

Refereed Conferences 179

Others 4

Total 372

***Publications* (Edited Books/Special Issues)**

4. **Qi Li (Lead), Paul Gao, Zhe-Sheng Chen, Hua Sui**, Special Issue “CAM in Cancer Treatment” will be published in *Journal of International Medical Research*, in press, 2016.

3. **Hiroshi Nakagawa (lead), Gert Fricker, Thomas Efferth, Yu Toyoda and Zhe-Sheng Chen**, Special Issue “Impacts of ABC transporters on human health: experimental and clinical evidences” will be published in a Special Issue in *BioMed Res Intern*, in press, 2016.

2. **Zhe-Sheng Chen and Dong-Hua Yang** Special Issue "Drugs/Radiation Resistance in Cancer Therapy", *Cancers*, in press, 2015.

1. **Zhe-Sheng Chen,** Hot Topics: ABC Transporters in Pharmacology/Physiology and Human Diseases, *Curr Pharm Biotechnol*, 2011.

***Publications*** **(Refereed Book Chapters)**

7. Ying-Jie Li, Yu-He Lei, Nan Yao, Nan Hu, Wen-Cai Ye, **Zhe-Sheng Chen**, and Dong-Mei Zhang, “Autophagy and Multi-Drug Resistance in Cancer”, Book Title: “The Research and Biology of Cancer”. 2016*,* iConcept Press

6. Atish Patel, De-Shen Wang, Hong-May Sim, Suresh V. Ambudkar and **Zhe-Sheng Chen**, “ABC Transporter Modulatory Drugs from Marine Sources: A New Approach To Overcome Drug Resistance in Cancer”, Book Title: ABC Transporters in Drug Resistant Tumors: Resistance of Targeted Anticancer Therapeutics, edited by Dr. Thomas Efferth, 2014, Springer Publishing Group.

5. Jian-Ge Qiu, Xiao-Long Mei, **Zhe-Sheng Chen**, and Zhi Shi, “Cytokine Detection by Flow Cytometry”, Book Title: Methods in Molecular Biology, Cytokine Bioassays, edited by Dr. Ivana Vancurova, 1172:235-42. doi: 10.1007/978-1-4939-0928-5\_21., 2014, Springer-Humana Press.

4. Xiao-Cong Huang, Priyank Kumar, Nagaragu Anreddy, Xue Xiao, Dong-Hua Yang and **Zhe-Sheng Chen**, “P-gp inhibitory activity from marine sponges, tunicates and algae”,Book Title:Anticancer drugs from marine origin, edited by Dr. Se-Kwon Kim, 2014, Springer publishers.

3. Rishil J. Kathawala, Charles R. Ashby Jr. and **Zhe-Sheng Chen**, “Molecular Mechanisms That Mediate Resistance to Paclitaxel in Cancer”, Book Title: Paclitaxel:Pharmacology, Clinical Uses, and Adverse Effect, in press, 2013, Nova Science Publishers, Inc.

2. Zhi Shi, Amit K. Tiwari, Charles R. Ashby Jr., Liwu Fu, and **Zhe-Sheng Chen**, “Anticancer role of Phosphodiesterase-5 inhibitors”, Book Title: “The Research and Biology of Cancer”. 2012*,* iConcept Press

1. Amit K. Tiwari, Dong-Hua Yang and **Zhe-Sheng Chen**, “Molecular Mechanisms of Methotrexate Resistance”, Book Title: Methotrexate: Pharmacology, Clinical Uses, and Adverse Effect (Hardback) Edited by [Valentina S. Castillo](http://www.bookdepository.com/search/advanced?searchAuthor=Valentina+S.+Castillo), Edited by [Laura A. Moyano](http://www.bookdepository.com/search/advanced?searchAuthor=Laura+A.+Moyano), March 01, 2012, Nova Science Publishers, Inc.

***Publications*** **(Refereed Journals) (#:contributed equally; \*:correspondent author)**

**2016**

183. Patel A, Zhang H, Wang DS, Yang DH, Dholakiya S, and **Chen ZS**.\* Pharmacotherapeutic

 options for Philadelphia chromosome-positive CML, submitted to *Acta Pharm Sin B*

 2016.

182. Zhang YK, Dai C, Yuan CG, Wu HC, Ziao Z, Fukuda Y, Le XC, Schuetz JD, Fu LW, and

 **Chen ZS**.\* Establishment and Characterization of Arsenic Trioxide Resistant KB/ATO cells,

 submitted to *Chin J Cancer*, 2016.

181. Zhang H, Patel A, Wang YJ, Zhang YK, Kathawala RJ, Qiu LH, Patel BA, Huang LH, Shukla

 S, Ambudkar SV, Fu LW\*, and **Chen ZS**.\* The BTK Inhibitor, Ibrutinib (PCI-32765)

 Overcomes Paclitaxel Resistance Resulting from the Overexpression of ABCB1 and ABCC10

 Transporters Submitted to *Mol Cancer Ther*, 2016.

180. Yang D, Li T, Kathawala RJ, Guo HQ, Yang DH, Chen X,Cheng CM\*, and **Chen ZS**\*.

 Derivatives of 2-Triﬂuoromethyl-2-hydroxypropionamide Reverse ABCG2(BCRP)-Mediated

 Multidrug Resistance: Synthesis and Biological Evaluations, submitted to *J Cell Biol*, 2015.

179. Patel A, Li TW, Anreddy N, Wang DS, Sodani K, Kathawala R, Yang DH, Cheng CM\*, and

 **Chen ZS**.\* Suppression of ABCG2 mediated MDR *in vitro* and *in vivo* by a novel inhibitor of

 ABCG2 drug transport, submitted to *Biochem Pharmacol*, 2015.

178. Kumar RV, Gupta P, **Chen ZS**, and Kwon CH.\* Synthesis and anticancer evaluation of sulfur

 Containing 9-anilinoacridines, submitted to *J Med Chem*, 2015.

177. Xu A, Luo S, Yao H, Cai H, Miao X, Yang DH, Wu F, Wu X, Yao H, Chen ZS, and Xu J.\*

 Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing

 Subcellular Localization to Mitochondria, *J Med Chem*, In press, 2016.

176. Zhang YK, Zhang GN, Wang YJ, Patel BA, Talele TT, Yang DH, and **Chen ZS**.\* Bafetinib

 (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and

 ABCG2 transporters, submitted to *Sci Rep*, In press, 2016.

175. Zheng YC, Yu B, **Chen ZS**, Liu Y, and Liu HM.\* TCPs：Privileged scaffolds for identifying

 potent LSD1 inhibitors for cancer therapy, *Epigenomics*, In press, 2015.

174. Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang DH\*, and **Chen ZS**.\* Overcoming

 ABC transporter-mediated MDR, a review on the molecular mechanisms and novel drug

 strategies, *Drug Resist Updat*, In press, 2016.

173. Gupta P, Khushboo J, Yang DH, Sadoqia M, Squillante E and **Chen ZS\***. Revisiting the role of

 nanoparticles as modulators of drug resistance and metabolism in cancer, *Expert Opin Drug*

*Metab Toxicol*, 12(3):281-9, 2016.

172. Zheng YC, Wang LZ, Zhao LJ, Zhao LJ, Zhan QN, Ma JL, Zhang B, Wang MM, Wang ZR,

 Li JF, Liu Y, **Chen ZS**, Shen DD, Liu XQ, Ren M, Lv WL, Zhao W, Duan YC\*, Liu HM\*.

 1,2,3-Triazole-Dithiocarbamate Hybrids, a Group of Novel Cell Active SIRT1 Inhibitors.

 *Cell Physiol Biochem*. 38(1):185-193, 2016.

171. Jones V, Huang RY, Chen LP, **Chen ZS**, Fu LW, and Huang RP\*. Cytokines in Cancer Drug

 Resistance: Cues to New Therapeutic Strategies, *BBA reviews on Cancer*, In press, 2016.

**2015 (21)**

170. Sui H, Zhou LH, Zhang YL, Huang JP, Liu X, Ji Q, Fu XL, Wen HT, **Chen ZS**, Deng WL\*,

 Zhu HR\*, Li Q\*. Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting

 p50/NF-κB Pathway in Colorectal Cancer. *J Cell Biochem*. In press, 2015.

169. Zhuo J, Hu J, Yang X, Chen M, Lei X, Deng L, Yao N, Peng Q, **Chen ZS**, Ye WC\*, and Zhang

 DM\*. Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and Apoptosis In

 Vitro and In Vivo. *Sci Rep*, 5:16185, 2015.

168. Wang YJ, Huang Y, Anreddy N, Zhang GN, Zhang YK, Xie M, Lin D, Yang DH,

Zhang M\*, and **Chen ZS\***, Tea nanoparticle, a safe and biocompatible nanocarrier, greatly

potentiates the anticancer activity of doxorubicin. *Oncotarget*, 7(5):5878-91, 2015.

167. Barbuti AM and **Chen ZS\***, Paclitaxel through the ages of anticancer therapy: an inducer of

 chemoresistance and sensitizer to radiation therapy. *Cancers*. 7(4):2360-71, 2015.

166. AnreddyN, Patel A, Zhang YK, Wang YJ, Shukla S, Kathawala RJ, Kumar P, Gupta P,

AmbudkarSV, Wurpel JND, **Chen ZS\***, and Guo H\*. A-803467, a tetrodotoxin-resistant

sodium channel blocker, modulates ABCG2-mediated MDR *in vitro* and *in vivo*. *Oncotarget*,

 6(36):39276-91, 2015.

165. Whitt JD, Keeton AB, Gary BD, Sklar L, Sodani K, **Chen ZS**, and Piazza GA\*. Sulindac

 Sulfide Selectively Increases Sensitivity of ABCC1 Expressing Tumor Cells to Doxorubicin

 and Glutathione Depletion. *J Biomed Res*, In press, 2015

164. Yao N, Li YJ, Zhang DM, Liu DL, Tang MK, Yiu A, Li Y, Chen WM, Lan P, Yao Z, **Chen**

**ZS**, and Ye WC\*. B4G2 induces mitochondrial apoptosis by the ROS-mediated opening of

Ca(2+)-dependent permeability transition pores. Cell Physiol Biochem. 37(3):838-52, 2015.

163.Huang Y, Wang YJ, Wang Y, Yi S, Fan Z, Sun L, Lin D, Anreddy N, Zhu H, Schmidt M,

**Chen ZS**, Zhang M\*. Exploring naturally occurring ivy nanoparticles as an alternative

biomaterial. *Acta Biomater*, 25: 268-83, 2015

162. Zhang GN, Ashby CRJ, Zhang YK, **Chen ZS\***, and Guo H\*. The reversal of antineoplastic

 drug resistance in cancer cells by β-elemene. *Chin J Cancer*, 34(3):45, 2015.

161.SinghaB, GatlaHR, PhyoS, PatelA, **Chen ZS**, and Vancurova I\*. IKK inhibition increases

 bortezomib effectiveness in ovarian cancer. *Oncotarget*, 6(28):26347-58, 2015.

160. Sui H, XuH, JiQ, LiuX, ZhouL, SongH, ZhouX, XuY, **Chen ZS**, Ji G\*, Li Q\*.

 5-HTR1D promotes metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway in

 colorectal cancer. *Oncotarget*, 6(28):25975-87, 2015.

159. Zhang YK, Zhang H, Zhang GN, Wang YJ, Kathawala RJ, Si R, Patel BA, Xu J\* and **Chen**

**ZS\***. Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal

 agents. Oncotarget, 6(27):24277-90, 2015.

158.Kathawala RJ, Wang YJ, Shukla S, Zhang YK, Alqahtani S, Kaddoumi A, Ambudkar

SV, Ashby CR\* and **Chen ZS\***. ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. *Chin J Cancer*, 34(3):115-20, 2015.

157.Zhang Y, Zhang YK, Wang YJ, Vispute SG, Jain S, Chen Y, Li J, Youssef DTA, El Sayed KA,

 **Chen ZS\*.** Esters of the Marine-Derived Triterpene Sipholenol A Reverse P-GP-Mediated

 Drug Resistance, *Mar. Drugs*, 13(4):2267-86, 2015.

156. Liu DL, Li YJ, Yang DH, Wang CR, Xu J, Yao N, Zhang XQ, **Chen ZS**, Ye WC, Zhang DM.

 Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug

 resistance in HepG2/ADM cells. *Int J Oncol*. 46(5):2029-38, 2015.

155. Zhang YK, Wang YJ, Gupta P, **Chen ZS\***. Multidrug Resistance Proteins (MRPs) and Cancer

 Therapy. *AAPS J*, 17(4):802-12, 2015 (IF: 3.9).

154. Kathawala RJ, Gupta P, Ashby CR Jr\*, **Chen ZS\***. The modulation of ABC transporter-

 mediated multidrug resistance in cancer: A review of the past decade. *Drug Resist Updat*,

 invited review, 18:1-17, 2015 (IF: 9.7)

153. Wei L, Lu J, Xu H, Patel A, **Chen ZS\***, Chen G\*. Silver nanoparticles: synthesis, properties, and therapeutic applications. *Drug Discov Today*. 20(5):595-601, 2015 (IF: 6.5).

152. Dai CL, Ma SL, Wang F, Zhao HY, Wu XP, Huang ZC, **Chen ZS**, Kenneth To and Fu LW. \* Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes, *Oncotarget*, 6(19):17738-52, 2015.

151. Hasinoff BB\*, Wu X, Yadavm AA, Patel D, Zhang H, Wang DS, **Chen ZS**, Yalowich JC.

Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II), *Biochem Pharmacol*, 93(3):266-76, 2015.

150. Kathawala RJ#, Wei L#, Anreddy N, Chen K, Patel A, Alqahtani S, Zhang YK, Wang YJ, Sodani

 K, Kaddoumi A, Ashby Jr. CR\*, **Chen ZS\***. The small molecule tyrosine kinase inhibitor NVP-

 BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and

 pharmacokinetic study, *Oncotarget*, 6(1):510-21, 2015.

**2014 （28）**

149. Wang J, Wang YJ, **Chen ZS**, Kwon CH\*, Synthesis and evaluation of sulfonylethyl-containing phosphotriesters of 3'-azido-3'-deoxythymidine as anticancer prodrugs, *Bioorg Med Chem*, 22(21):547-56, 2014.

148. Sui H, Cai GX, Pan SF, Deng WL, Wang Y, **Chen ZS**, Cai SJ, Zhu HR, Li Q\*. miR-200c attenuates P-gp mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer. *Mol Cancer Ther* 13(12):3137-51, 2014.

147. Wang YJ, Zhang YK, Kathawala RJ, **Chen ZS\***. Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-binding Cassette Transporters in Anticancer Drug Resistance. *Cancers* (Basel) 6(4)1925-52, 2014.

146. Minami K, Kamijo Y, Nishizawa Y, Tabata S, Horikuchi F, Yamamoto M, Kawahara K, Shinsato Y, Tachiwada T, **Chen ZS**, Tsujikawa K, Nakagawa M, Seki N, Akiyama S, Arima K, Takeda Y, Furukawa T.\* Expression of ABCB6 Is Related to Resistance to 5-FU, SN-38 and Vincristine. *Anticancer Res*. 34(9):4767-73, 2014

145. Anreddy N, Gupta P, Kathawala RJ, Patel A, Wurpel JN, **Chen ZS\***. Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. *Molecules*. 19(9):13848-13877. Invited Review. 2014.

144. Wang DS, Rizwani GH\*, Guo H, Ahmed M, Ahmed M, Hassan SZ, Hassan A, **Chen ZS**, Xu RH. Annona squamosa Linn: Cytotoxic activity found in leaf extract against human tumor cell lines. *Pak J Pharm Sci*. (5 Spec No):1559-63, 2014.

143. Zhang H#, Patel A#, Ma SL, Li XJ, Zhang YK, Yang PQ, Kathawala RJ, Wang YJ, Anreddy N, Fu LW\*, **Chen ZS\***. In vitro, in vivo and ex-vivo characterization of ibrutinib: A potent inhibitor of MRP1 efflux function. *Br J Pharmacol*. 171(24)5845-57, 2014.

142. Tang SJ, Chen LK, Wang F, Zhang YK, Huang ZC, To KK, Wang XK, Talele TT, **Chen ZS**, Chen WQ, Fu LW.\* CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. *Biochem Pharmacol*, 91(2): 144-56, 2014. (IF: 4.6)

141 Huang XC, Xiao X, Zhang YK, Talele TT, Salim A, **Chen ZS\***, and Capton RJ\*. Lamellarin O,

 a pyrrole alkaloid from a marine sponge Ianthella sp., reverses P-gp and BCRP mediated drug

resistance. *Marine Drugs*, 12(7):3818-37, 2014. (IF: 3.99)

140. Singh S, Prasad NR, Chufan EE, Patel BA, Wang YJ, **Chen ZS**, Ambudkar S.V\*, Talele

T.T.\* Design and Synthesis of Human ABCB1 (P-Glycoprotein) Inhibitors by Peptide Coupling

of Diverse Chemical Scaffolds on Carboxyl and Amino Termini of (S)-Valine-Derived Thiazole

Amino Acid. *J Med Chem*, 57(10):4058-72, 2014. (IF: 5.6)

139. Zhang H, Zhang YK, Wang YJ, Kathawala RJ, Patel A, Sodani K, Talele TT, Ambudkar

 SV, **Chen ZS\***, and Fu LW\*. WHI-P154 enhances the chemotherapeutic effect of anticancer

 agents in ABCG2-overexpressing cells. *Cancer Sci*, 105(8):1071-8, 2014. (IF: 3.5)

138. Xu S, Pei L, Wang C, Zhang YK, Li D, Yao H, Wu X, **Chen ZS\***, Sun Y,and Xu J\*. Novel

 hybrids of natural oridonin bearing nitrogen mustards as potential anticancer drug candidates.

 *ACS Med Chem Lett*, 5(7):797-802, 2014. (IF: 3.3)

137. Wang DS#, Patel A#, Shukla S, Zhang YK, Wang YJ, Kathawala RJ, Robey RW, Yang DH,

 Talele TT, Bates SE, Ambudkar SV, Xu RH\*, and **Chen ZS\***. Icotinib antagonizes ABCG2-

 mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate

 synthase and ABCG2. *Oncotarget*, 5(12):4529-42, 2014. (IF: 6.6)

136. Liu DL, Li YJ, Yao N, Xu J, **Chen ZS**, Yiu A, Zhang C.X, Ye WC\*, Zhang DM\*.Acerinol, a

 cyclolanstane triterpenoid from *Cimicifuga acerina*, reverses ABCB1-mediated multidrug

 resistance in HepG2/ADM and MCF-7/ADR cells. *Europ J Pharmacol*, 733:34-44, 2014. (IF:

 2.8).

1. Wang YJ, Kathawala RJ, Zhang YK, Patel A, Kumar P, Shukla S, Fung KL, Ambudkar SV, Talele TT, **Chen ZS\***. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. *Biochem Pharmacol*, 90(4):367-78, 2014. (IF: 4.6)

134. Zhang H, Wang YJ, Zhang YK, Wang DS, Kathawala RJ, Patel A, Talele TT, **Chen ZS\***, Fu

LW\*. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. *Cancer Lett*, 350(1-2):61-8, 2014. (IF: 4.3)

133. Sodani K, Tiwari AK, Dai CL, Abuznait AH, Xiao ZJ, Patel A, Ashby JrCR, Kaddoumi A, Fu LW, and **Chen ZS\***. Sildenafil enhances the anticancer activity of paclitaxel in an ABCB1-mediated multidrug resistance xenograft mouse model. *J Cancer Res Updat*, 3, 169-173, 2014.

132. Zhang H, Kathawala RJ, Wang YJ, Zhang YK, Patel A, Shukla S, Robey RW, Talele TT,

Ashby JrCR, Ambudkar SV, Bates SE, Fu LW\*, and **Chen ZS\*.** Linsitinib (OSI-906)

antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-

mediated drug resistance. *Intern J Biochem Cell Biol*, 51:111-9, 2014. (IF; 4.2)

131. Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele

TT, and **Chen ZS\*.** Telatinib reverses chemotherapeutic multidrug resistance mediated by

ABCG2 efflux transporter *in vitro* and *in vivo***.** *Biochem Pharmacol*, 89(1):52-61, 2014.

130. Anreddy N, Patel A, Sodani K, Kathawala RJ, Chen EP, Wurpel JND, and **Chen ZS**\*. PD173074, a Selective FGFR Inhibitor, Reverses MRP7 (ABCC10)-Mediated MDR. *Acta Pharm Sin B*. 4(3):202-7, 2014.

129. Wang DS, Patel A, Sim HM, Zhang YK, Wang YJ, Kathawala RJ, Zhang H, Talele TT, Ambudkar SV, Xu RH.\*, and **Chen ZS**\*. ARRY-334543 Reverses Multidrug Resistance by Antagonizing the Activity of ATP-Binding Cassette Subfamily G Member. *J Cell Biochem*, 115(8):1381-91, 2014.

128. Kathawala RJ, Chen JJ, Zhang YK, Wang YJ, Patel A, Wang DS, Talele TT, Ashby CR\*, and

**Chen ZS**\*. Masitinib antagonizes ATP-binding cassette subfamily G member 2 mediated

multi-drug resistance. *Intern J Oncol*, 44(5):1634-42, 2014.

127. Yao N, Liu DL, Li YJ, **Chen ZS**, Shi Z, Chen WM, Yao Z, Zhang DM\*, and Ye WC\*. B5H7, a morpholine derivative of 23-hydroxybetulinic acid, reverses doxorubicin resistance in HepG2/ADM. *J Cancer Res Updat*, 3:59-66, 2014.

126. Kathawala RJ, Sodani K, Chen K, Patel A, Abuznait AH, Anreddy N, Sun YL, Kaddoumi A,

Ashby CR\*, and **Chen ZS\***. Masitinib antagonizes ATP-binding cassette subfamily C member

10-mediated paclitaxel resistance: A priclinical study. *Mol Cancer Ther*, 44(5):1634-42, 2014.

125. Sun YL, Kumar P, Sodani K, Patel A, Pan Y, Baer MR, **Chen ZS**\* and Jiang WQ\*.Ponatinib

enhances anticancer drug sensitivity in MRP7-overexpressing cells. *Oncol Rep*, 31(4):1605-12,

2014 (IF: 2.2).

124. Chen G\*, Chen R, Zou C, Yang D and **Chen ZS.** Fragmented polymer nanotubes from

sonication-induced scission with thermo-responsive gating system for anti-cancer drug delivery. *J Mater Chem B*. **2:** 1327-1334, 2014 (IF: 6.01)

123. Kathawala RJ, Wang YJ, Ashby Jr. CR\*, and **Chen ZS\***. Recent advances regarding the

 role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. *Chin J*

 *Cancer*. 33(5):223-30, 2014.

122. Yan XJ, Gong LH, Zheng FY, Cheng KJ, **Chen ZS**\*, and Shi, Z\*. Triterpenes and

 triterpenoids as reversal agents for anticancer drug resistance treatment. *Drug Discov Todays*.

 19(4):482-8, 2014. (IF: 6.7)

**2013 （17）**

121. Guo HQ\*, Zhang GN, Wang YJ, Zhang YK, Sodani K, Talele TT, Ashby Jr. CR,

and **Chen ZS\*.** β-Elemene, a compound derived from *Rihizoma zedoariae*, reverses

multidrug resistance mediated by ABCB1 transporter. *Oncol Rep* 31(2):858-66, 2013(IF: 2.3)

120. Yang D, Kathawala RJ, Chufan EE, Patel A, Ambudkar SV, **Chen ZS** and Chen X\*.

Tivozanib Reverses Multidrug Resistance Mediated by ABCB1 (P-glycoprotein) and ABCG2

(BCRP). *Future Oncol*, in press, 2013 (IF:3.2).

119. Vispute SG, Chen JJ, Sun YL, Sodani K, Singh S, Pan YH, Talele TT, Ashby CR.

 Jr\*, and **Chen ZS\*.** Vemurafenib (PLX4032, Zelboraf®), a BRAF inhibitor, modulates

 ABCB1-, ABCG2-, and ABCC10-mediated multidrug resistance. *J Cancer Res Updat*. 2:306-

 317, 2013.

118. Guo HQ, Wang DS, Rizwani GH\*, Ahmed M, Hassan A, Xu RH, Ahmed M, Mansoor N, Tiwari

 AK, and **Chen ZS** Antineoplastic activity of *Holoptelea integrifolia* (Roxb) Planch bark extracts.

 *Pakistan J Pharm Sci*. 26(6):1151-1156, 2013. (IF: 1.1)

117. Chen JJ, Sodani K, Xiao ZJ, Tiwari AK, Patel A, Zhang DM, Yang DH, Ye WC, Chen SD\*, and **Chen ZS**\*. BBA, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10), *PLoS ONE,* 8(9): e74573, 2013.

116. Chen J, Brown DP\*, Wang YJ, and **Chen ZS.** New phenstatin-fatty acid conjugates:

 synthesis and evaluation. *Bioorg & Med Chem Lett*, 23(18):5119-22, 2013. (IF: 2.5)

115. Tiwari AK\*, and **Chen ZS**. Repurposing phosphodiesterase 5 inhibitors as

 chemoadjuvants. editorial, *Front Pharmacol*. 4(82): 1-3, 2013.

114. Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R,

and **Chen ZS**\*. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug

resistance in cancer cells. *Cancer Chemother Pharmacol*.72(1):189-99, 2013. (IF: 2.8)

113. Deng W, Hu B, Dai CL, Wang YJ, Chen HF, Zito SW, Fu LW, and **Chen ZS\***.

 Anticancer Activity of Oldenlandia Diffusa and Viola Philippica Car. *J Cancer Res Updat*,

 2 (2): 87-94, 2013.

112. Huang XC, Sun YL, Salim A, **Chen ZS**\*, and Capon RJ\* Parguerenes: Marine red alga

 bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer

 cells. *Biochem Pharmacol*, 85(9):1257-68, 2013.

111. Zhao XQ, Dai CL, Ohnuma S, Liang YJ, Deng W, Zeng MS, Ambudkar SV, **Chen ZS\***, and

Fu LW\*. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibitingthe function

of ATP-binding cassette subfamily G member 2. *Eur J Pharm Sci*, 49(3):441-50, 2013.

110. Deng W, Dai CL, Chen JJ, Kathawala R, Sun YL, Chen HF, and **Chen ZS\***.

 Tandutinib (MLN518) Reverses Multidrug Resistance by Inhibiting the Efflux Activity of the

 MRP7 (ABCC10). *Oncol Rep*, 29(6):2479-85, 2013. (IF: 2.3)

109. Zhang DM\*, Li YJ, Shu C, Ruan ZX, Chen WM, Yiu A, Wang J, Yao Z, Fung KP, Fu LW,

**Chen ZS**, and Ye WC. Bipiperidinyl derivates of 23-hydroxybetulinic acid reverse the

resistance of HepG2/ADM and MCF-7/ADR cells**,** *Anti-Cancer Drugs*, 24(5):441-

54, 2013. (IF: 2.4)

108. Sun YL, Chen JJ, Kumar P, Sodani K, Patel A, Chen YL, Chen SD, Jiang WQ\*,

 **Chen ZS\***. Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar,

 *PLoS ONE,* 8(2):e55576, 2013. (IF: 4.2)

107. He D, Zhao XQ, Chen XG, Fang Y, Singh S, Talele TT, Qiu HJ, Liang YJ, Wang XK, Zhang

GQ\*, **Chen ZS**, Fu LW\*. BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase,

Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells, *PloS*

*ONE*, 8(1):e54181, 2013. (IF: 4.2)

106. Natarajan K, Bhullar J, Shukla S, Burcu M, **Chen ZS**, Ambudkar SV, Baer MR\*

The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein

(ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-

dependent and independent mechanisms, *Biochem Pharmacol*, 85:514-24., 2013. (IF: 4.7)

105. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Patel A, Talele TT, Fu LW,

Kaddoumi A\*, Gallo JM, **Chen ZS**\*.Nilotinib potentiates anticancer drug sensitivity in

murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models.

*Cancer Lett*, 328: 307-17, 2013.

**2012 （17）**

104. Zhang DM, Shu C, Chen JJ, Sodani K, Wang J, Bhatnagar J, Lan P, Ruan ZX, Xiao ZJ,

Ambudkar SV, Chen WM, **Chen ZS**\*, Ye WC\*. BBA, A novel 23-hydroxybetulinic acid

derivative, potently reverses ABCB1-mediated drug resistance *in vitro* and *in vivo*,

*Mol Pharm*, 9: 3147-59, 2012. (IF: 5.2)

103. Kuang YH, Patel J, Sodani K, WuCP, Liao LQ, Patel P, Tiwari AK, Dai CL, Chen X\*,

Fu LW, Ambudkar SV, Korlipara VL\*, **Chen ZS\*.** OSI-930 analoues as novel reversal agents

for ABCG2-mediated MDR. *Biochem Pharmacol*, 84:766-74, 2012. (IF:4.5)

102.Li TW, Yang YC, Cheng CM\*, Tiwari AK, Sodani K, Zhao YF, Abraham I, **Chen ZS.**

 N-arylphenyl-2, 2-dichloroacetamide analogues as anti-cancer agents: design, synthesis and

 biological evaluation, *Bioorg Med Chem Lett*, 22: 7268-74, 2012. (IF: 2.5)

101. Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB,Cai L, **Chen ZS,** Ambudkar SV, and

 Baer MR\*. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the

 multidrug resistance-associated ATP-binding cassette transporter ABCG2, *Mol Cancer*

 *Ther*, 2012. (IF: 5.3)

100. Kumar P, Zhang DM, Degenhardt K\*, and **Chen ZS**\*. Autophagy and drug resistance,

 invited review, *Cells*, 1(3): 558-75, 2012.

99. Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Yang DH, Jiang WQ, Chen SD\*, and **Chen**

 **ZS\*,** Sildenafil and vardenafil reverse multidrug resistance by inhibiting the efflux function of

 MRP7 (ABCC10) transporter, *Cancer Sci*, 103(8): 1531-7, 2012. (IF: 3.8)

98. Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q, Zhu J, Chen JJ, Huang RC, **Chen ZS**, and

 Huang RP\*. Enhanced chemosensitization in multidrug-resistant human breast cancer

cells by inhibition of IL-6 and IL-8 production. *Breast Cancer Res Treatment*, 135(3):737-47, 2012. (IF: 4.2)

97. Liu KJ, Su XD, Xie JD, Chen X, Wang F, Liang Y, Singh A, Talele TT, Sun YL, **Chen ZS**, Wu

 HY, and Fu LW\*. Saracatinib (AZD0530) Is a Potent Modulator of ABCB1-mediated Multidrug

 Resistance in Vitro and in Vivo. *Int J Cancer*, 132 (1):224-35, 2012. (IF: 5.5)

96. Cheng C, Liu ZG, Zhang H, Xie JD, Chen XG, Zhao XQ, Wang F, Liang YJ, Chen LK, Singh

 S, Chen JJ, Talele TT, **Chen ZS,** Zhong FT, and Fu LW\*. Enhancing Chemosensitivity in

 ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-Like Cells by An Aurora Kinase

 Inhibitor CCT129202 *Mol Pharm*, 9:1971-82, 2012 (IF: 5.2)

95. Abraham I, El Sayed K, **Chen ZS**\*, and Guo HQ\*. Current status on marine products with

 reversal effect of multidrug resistance in cancer. *Marine Drugs*, 10:2312-21, 2012 (IF: 3.8)

94. Zhao XQ, Xie JD, Chen X, Sim HM, Zhang X, Ling Y, Singh S, Talele TT, Ambudkar SV,

 **Chen ZS,** and Fu LW\*. Neratinib (HKI-272) Reverses ABCB1-Mediated Chemotherapeutic

Drug Resistance *in vitro, in vivo* and *ex vivo,* *Mol Pharmacol*, 82:47-58, 2012. (IF: 4.5)

93. Sodani K, Tiwari AK, Singh S, Patel A, Xiao ZJ, Chen JJ, Sun YL, Talele TT, **Chen ZS\*.**

 GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and

 ABCB1-mediated drug resistance. *Biochem Pharmacol*, 15;83(12):1613-22, 2012. (IF: 4.2)

92. Sun YL, Kathawala RJ, Singh S, Zheng K, Talele TT, Jiang WQ\*, and **Chen ZS\*.**

 Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug

 Resistance. *Anti-Cancer Drugs*, 23(8):865-73., 2012. (IF: 2.3)

91. Sun YL, Patel A, Kumar P, **Chen ZS\*.** Role of ABC transporters in cancer chemotherapy. *Chin J Cancer*, editorial, 31(2):51-7., 2012.

90. Shukla S, **Chen ZS**, and Ambudkar SV\*. Tyrosine kinase inhibitors as modulators of ABC

 transporter-mediated drug resistance. *Drug Resist. Updat.,* invited review, Feb 8, 2012 (IF: 12.5)

 Selected as a top25 most cited article in ScienceDirect.

89. Sodani K, Patel A, Kathawala RJ, **Chen ZS\***. Multidrug resistance associated proteins in

 multidrug resistance. *Chin J Cancer*, invited review, 31(2):58-72, 2012.

88. Peng XX, Tiwari AK, Wu HC, and **Chen ZS\*.** Overexpression of P-glycoprotein induces

 acquired resistance to imatinib in chronic myeloid. *Chin J Cancer*, 31(2):110-8, 2012.

**2011 （11）**

87. Patel J, Kuang YH, **Chen ZS**, and Korlipara V\*. Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930. *BioorganicMed Chem Lett*, 21(21):6495-9, 2011. (IF: 2.5)

86. Yan YY, Zheng LS, Zhang X, Chen LK, Singh S, Wang F, Zhang JY, Liang YJ, Dai CL, Gu LQ, Zeng MS, Talele TT, **Chen ZS,** and Fu LW\*. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. *Mol Pharm*, 8(5):1687-97. 2011. (IF: 5.2)

85. **Chen ZS\*,** and Tiwari AK. Multidrug Resistance Proteins (MRPs/ABCCs) in Cancer Chemotherapy and Genetic Diseases, invited review, *FEBS J*, 278: 3226–3245, 2011. (IF: 3.8)

84. Peng XX, Shi Z, Damaraju VL, Tiwari AK, Fu LW, Cass CE, Ashby CR Jr, Kruh GD, and **Chen Z S\***. Up-regulation of P-gp in human chronic myeloid leukemia cells with acquired resistance to 6-mercaptopurine. *Oncol Lett*, 2 (3): 549-56, 2011.

83. Li X, Xu H, **Chen ZS**, and Chen G\*. Biosynthesis of nanoparticles by microorganisms and their applications, invited review article, *J. Nanomaterials*, 2011, Article ID 270974, 16 pages. (IF: 1.9)

82. Shi Z, Tiwari AK, Patel AS, Fu LW\*, and **Chen ZS\*.** Roles for sildenafil in enhancing drug sensitivity in cancer, invited review article. *Cancer Res*, 71 (11): 3735-8, 2011.

81. Hopper-BorgeEA, Churchill T, Paulose C, Nicolas E, Jacobs JD, Ngo O, Kuang YH, Grinberg A, Westphal H, **Chen ZS**, Klein-Szanto A, Belinsky MG,and Kruh KD. Contribution of Abcc10 (Mrp7) to *in vivo* paclitaxel resistance as assessed in *Abcc10-/-* mice. *Cancer Res*, 71 (10): 3649-57, 2011.

80. **Chen ZS\***. (Guest Editor) Hot Topics: ABC Transporters in Pharmacology/Physiology and Human Diseases. *Curr Pharm Biotech*, Editorial, 12(4): 569, 2011. (IF: 3.4)

79. Tiwari AK, Sodani K, Dai CL, Ashby CRJr, **Chen ZS\***.Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy, invited review article, *Curr Pharm Biotech*, 12(4): 570-94, 2011. (IF: 3.4)

78. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng XX, Abraham I, Ambudkar SV, Talele TT, Fu LW.\*, **Chen ZS\***.Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. *Cancer Res*, 71(8): 3029-41, 2011. (IF: 7.7)

77. Ding PR, Tiwari AK, Ohnuma S, Lee JWKK, An X, Dai CL, Lu QS, Singh S, Talele TT, Ambudkar SV, **Chen ZS**.\* The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of the ABC Transporter ABCB1/P-glycoprotein. *PLoS ONE*, 6 (4): e19329, 2011.12.(IF: 4.2)

**2010 （5）**

76. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK,

 Ma XX, To KK, Ambudkar SV, **Chen ZS**, Fu LW\*. Apatinib (YN968D1) Reverses Multidrug

 Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters.

 *Cancer Res*, 70: 7981-91, 2010. (IF: 7.7)

75. Abraham I, Jain S, Wu CP, Khanfar M, Kuang Y, Dai CL, Shi Z, Chen X, Fu L, Ambudkar SV, El Sayed K, **Chen ZS**.\* Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells, *Biochem Pharmacol*, 80 (10): 1497-506, 2010. (IF: 4.2)

74. An X, Sun YB, Tiwari AK, Ding PR, Ashby CR Jr, **Chen ZS**.\* BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review, *Leuk Res*, 34: 696-7, 2010. (IF: 2.3)

73. TiwariAK, An X, **Chen ZS**.\* The Role of Stem Cell Markers in Multidrug Resistance Mediated by ABC Transporters, *Leuk Res*, Editorial, 34:696-7, 2010. (IF: 2.3)

72. Kuang YH, Shen T, Chen X\*, Sodani K, Hopper-Borge E, Tiwari AK, Lee JWKK, Fu L, **Chen ZS\*** Lapatinib and erlotinib are potent reversal agents for ABCC10/MRP7-mediated multidrug resistance. *Biochem Pharmacol*, 79(2):154-61, 2010. (IF: 4.2)

**2009 （12）**

71. Shen T, Kuang YH, Ashby Jr CR, Lei Y, Chen A, Zhou Y, Chen X, Tiwari AK, Hopper-Borge E, Ouyang J, **Chen ZS\*.** Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). *PloS ONE*, 10: e7520, 2009. (IF: 4.2)

70. Tiwari AK\*, Sodani K, **Chen ZS.\*** Current advances in modulation of ABC transporter-mediated multidrug resistance in cancer (invited review paper). *Intern J Toxicol Pharm Res*, 1(1): 1-6, 2009.

69. [Dai CL](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dai%20CL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Liang YJ](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Liang%20YJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Chen LM](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chen%20LM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Zhang X](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zhang%20X%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Deng WJ](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Deng%20WJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Su XD](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Su%20XD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Shi Z](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shi%20Z%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Wu CP](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wu%20CP%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Ashby CR Jr](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ashby%20CR%20Jr%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Akiyama S](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Akiyama%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Ambudkar SV](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ambudkar%20SV%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [**Chen ZS**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chen%20ZS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract)**\***, [Fu LW](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fu%20LW%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract)\* Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. *Biochem Pharmacol*, 78: 355-64, 2009. (IF: 4.2)

68. Jain S, Abraham I, Carvalho P, Kuang YH, Shaala LA, Youssef DT, Avery MA, **Chen ZS,** and El Sayed KA.\* Sipholane triterpenoids:chemistry, reversal of ABCB1/P-glycoprotein-mediated multidrug resistance, and pharmacophore modeling. *J Nat Prod*, 72 (7): 1291-8, 2009. (IF: 3.1)

67. Tiwari AK, Kamlesh S, Wang SR, Kuang YH, Ashby CR Jr, Chen X, and **Chen ZS**.\* Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. *Biochem Pharmacol*, 78: 153-61, 2009. (IF: 4.2) <http://top25.sciencedirect.com/subject/pharmacology-toxicology-and-pharmaceutical-science/20/journal/biochemical-pharmacology/00062952/archive/22/>

66. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, **Chen ZS**, Tong XZ, Fu LW.\* [Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.](http://www.ncbi.nlm.nih.gov/pubmed/19232821?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=14) *Cancer Lett*, 279: 74-83, 2009. (IF: 4.3)

65. Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW\*, Shao Y, Chen YM, Zang F, and **Chen ZS**.\* The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. *Oncol Rep*, 21: 483-9, 2009. (IF: 1.8)

64. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Furukawa T, Akiyama S, Peng XX, Ashby CR Jr, Kruh GD, and **Chen ZS**.\* Cepharanthine is a potent reversal agent for MRP7-mediated multidrug resistance. *Biochem Pharmacol*, 77: 993-1001, 2009. (IF: 4.2)

63. Shi Z, Tiwari AK, Shukla S, Robey RW, Kim I-W, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW,\* Ambudkar SV, and **Chen ZS**.\* Inhibiting the Function of ABCB1 and ABCG2 by the EGFR Tyrosine Kinase Inhibitor AG1478. *Biochem Pharmacol*, 77: 781-93, 2009. (IF: 4.2)

62. Guo Y, Kock K, Ritter CA\*, **Chen ZS**, Grube M, Jedlitschky G, Illmer M, Beck JF, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, and Schaich M. Expression of ABCC type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long term survival. *Clin Cancer Res*, 15: 1762-9, 2009. (IF: 7.3)

61. Kuang YH, Chen X\*, Su J, Wu LS, Liao LQ, Li D, **Chen ZS**, and Kanekura T.\* RNA interference targeting the CD147 induces apoptosis of multidrug resistant cancer related to XIAP depletion. *Cancer Lett*, *276*:189-95, 2009. (IF: 4.3)

60. Hopper-Borge E, Xu X, Shen T, Shi Z, **Chen ZS,** and Kruh GD.\* Human multidrug resistance Protein 7 (ABCC10) is a resistance factor for nucleoside analogs and epothilone B. *Cancer Res*, 69: 178-84, 2009. (IF: 7.7)

**2008 (3)**

59. [Kuang YH](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kuang%20YH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Chen X](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chen%20X%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus),\* [Su J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Su%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Wu LS](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wu%20LS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Li J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Li%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Chang J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chang%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Qiu Y](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Qiu%20Y%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [**Chen ZS**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chen%20ZS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), and [Kanekura T](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kanekura%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus).\* Proteome Analysis of Multidrug Resistance of Human Oral Squamous Carcinoma Cells Using CD147 Silencing. *J Proteome Res*, 7: 4784-4791, 2008. (IF: 5.5)

58. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR. Jr, Huang Y, Robey RW, Liang YJ, Chen L, Shi CJ,Ambudkar SV, **Chen ZS**,\* and Fu LW\*. Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. *Cancer Res*, 68: 7905-14, 2008. (IF: 7.7)

57. Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, Zhou Y, Tiwari AK, Fu LW, Cass CE, and **Chen ZS.\*** Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. *Leuk Res*, 32: 799-809, 2008. (IF:2.3)

**2007 (6)**

56. Wang L, Sun J, Li YQ, **Chen ZS**, Akiyama S, and Xian LJ.\* Reversal effect of BM0cyclin 1 on multidrug resistance in C-A120 cells. *Anticancer Drugs*, 18: 1015-21, 2007. (IF: 2.3)

55. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR. Jr, Fu LW\*,

 Ambudkar SV, and **Chen ZS**.\* Erlotinib (Tarceva, OSI-774) Antagonizes ABCB1(P-

 glycoprotein)- and ABCG2-mediated Drug Resistance. *Cancer Res* 67: 11012-20, 2007. (IF: 7.7)

54. Tachiwada T, **Chen ZS.** Che XF, Matsumoto M, Haraguchi M, Gotanda T, Sumizawa T, Furukawa T, Nishiyama K, Seki N, Yamamoto M, Nakagawa M, and Akiyama SI.\* Isolation and characterization of arsenite-resistant human epidermoid carcinoma KB cells. *Oncol Rep*, 18 (3): 721-7, 2007. (IF: 1.8)

53. Shi Z, Jain S, Kim I-W, Peng XX, Abraham I, Fu LW\*, Youssef DT, El Sayed KA, Ambudkar SV, and **Chen ZS.\*** Siphoelnol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. *Cancer Sci*, 98 (9): 1373-80, 2007. (IF: 3.77)

52. Jain S, Laphookhieo S, Shi Z, Fu LW, Akiyama S, **Chen ZS**, Youssef DTA, van Soest RWM, El Sayed KA.\* Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids. *J Nat Prod*, 70 (6): 928-31, 2007 (IF: 3.1)

51. Shi Z, Liang Y, **Chen ZS**, Wang XH, Ding Y, Chen L, and Fu LW.\* Overexpression of survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. *Oncol Rep*, 17 (4): 969-76, 2007. (IF:1.8)

**2006 (2)**

50. Kruh GD\*, Guo Y, Hopper-Borge E, Belinsky MG, and **Chen ZS.** ABCC10, ABCC11, and ABCC12. Europ J Physiol (Pflugers Arch). 453 (5), 675-84, 2006. (IF: 3.7)

49. Shi Z, Liang Y, **Chen ZS,** Wang XW, Wang XH, Ding Y, Chen L, Yang XP, and Fu LW.\* Stable reversal of MDR1/P-glycoprotein –mediated multidrug resistance by EGFP vector basesd RNA interference. *Cancer Biol Ther*, 5: 39-47, 2006. (IF: 3.2)

**2005 (2)**

48. Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, **Chen ZS**, Grinberg A, Wesrphal H, Lerro A, and Kruh GD.\* Analysis of the in vivo functions of mrp3: Mrp3 is an alternate export route for bile acids and glucuronides in cholestatic hepatocytes. *Mol Pharmacol*. 68: 160-8, 2005. (IF: 4.5)

47 **Chen ZS**, Guo Y, Belinsky MG, Kotova E, and Kruh GD.\* Transport of bile acids, sulfated steroids, estradiol 17-B-D-Glucuronide and leukotriene C4 by Human Resistance Protein 8 (MRP8, ABCC11). *Mol Pharmacol* 67: 545-57, 2005. (IF: 4.5)

**2004 (1)**

46. Hopper-Borge E, **Chen ZS**, Shchaveleva I, Belinsky MG, and Kruh GD.\* Analysis of the drug resistance profile of MRP7 (ABCC10): Resistance to docetaxel. *Cancer Res*, 64: 4927-30, 2004. (IF: 7.7)

**2003 (3)**

45. Guo Y, Kotova E, **Chen ZS**, Lee K, Hopper-Borge E, Belinsky MG, and Kruh GD.\* MRP8 (ABCC11) is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines, 2'3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)-adenine. *J Biol Chem*, 278: 29509-14, 2003. (IF: 4.7)

44. **Chen ZS**, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, and Kruh GD.\* Transport of methotrexate, methotrexate polyglutamates and 17B-Estrodiol 17-(B-D-glucuronide) by ABCG2 (BCRP/MXR): Effects of acquired mutations at R482 on methotrexate transport. *Cancer Res*, 63: 4048-54, 2003. (IF: 7.7)

43. **Chen ZS**, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, and Kruh GD.\* Characterization of the transport properties of multidrug resistance protein 7 (MRP7, ABCC10). *Mol Pharmacol*, *63:* 351-8, 2003. (IF: 4.5)

**2002 (4)**

42. Belinsky MG, **Chen ZS**, Shchaveleva I, Zeng H, and Kruh GD.\* Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). *Cancer Res*, *62:* 6172-7, 2002. (IF: 7.7)

41. Haraguchi M, Tsujimoto H, Fukushima M, Higuchi I, Kuribayashi H, Utsumi H, Nakayama A, Hashizume Y, Hirato J, Yoshida H, Hara H, Hamano S, Kawaguchi H, Furukawa T, Miyazono K, Ishikawa F, Toyoshima H, Kaname T, Komatsu M, **Chen ZS**, Gotanda T, Tachiwada T, Sumizawa T, Miyadera K, Osame M, Noda T, Yamada Y, and Akiyama S.\* Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice. *Mol Cell Biol*, *22:* 5212-21, 2002. (IF: 12.0)

40. Mukai M, Kanzaki A, **Chen ZS**, Miyashita H, Sumizawa T, Furukawa T, Haraguchi M, Takebayashi Y, Takamatsu H, and Akiyama S.\* Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. *Oncol Rep*, *9:* 839-44, 2002. (IF: 1.8)

39 **Chen ZS**, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD.\* Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. *Cancer Res*, *62:* 3144-50, 2002. (IF: 7.7)

**2001 (8)**

38. Kruh GD\*, Zeng H, Rea PA, Liu G, **Chen ZS**, Lee K, and Belinsky MG. MRP subfamily transporters and resistance to anticancer agents. *J Bioenergic Biomembrane*, *33:* 493-501, 2001. (IF: 3.7)

37 Zeng H, **Chen ZS**, Belinsky MG, Rea PA, and Kruh GD.\* Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP)3 and MRP1: effect of polyglutamylation on MTX transport. *Cancer Re*s, *61:* 7225-32, 2001. (IF: 7.7)

36 Ohno N, Tani A, **Chen ZS**, Uozumi K, Hanada S, Akiba S, Ren XQ, Furukawa T, Sumizawa T, Arima T, and Akiyama SI.\* Prognostic significance of multidrug resistance protein in adult T-cell leukemia. *Clin Cancer Res*, *7:* 3120-26, 2001. (IF: 6.7)

35 **Chen ZS,#** Lee K,# and Kruh GD.\* Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. *J Biol Chem*, *276:* 33747-54, 2001. (IF: 4.7)

34 Murakami T, Shibuya I, Ise T, **Chen ZS**, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y, and Kohno K.\* Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. *Intern J Cancer*, *93:* 869-74, 2001. (IF: 5.5)

33 Aoki S, **Chen ZS**, Higasiyama K, Setiawan A, Akiyama S, and Kobayashi M.\* Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells. *Jap J Cancer Res*, *92:* 886-95, 2001(IF: 3.77)

32 **Chen ZS,** Aoki S, Komatsu M, Ueda K, Sumizawa T, Furukawa T, Okumura H, Ren X Q, Belinsky MG, Lee K, Kruh GD, Kobayashi M, and Akiyama S.\* Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. *Intern J Cancer*, *93:* 107-13, 2001. (IF: 5.5)

31 Ren XQ, Furukawa T, Aoki S, Nakajima T, Sumizawa T, Haraguchi M, **Chen ZS**, Kobayashi M, and Akiyama S.\* Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. *J Biol Chem*, *276:* 23197-206, 2001. (IF: 4.7)

**2000 (5)**

30 Okumura H, **Chen ZS,** Sakou M, Sumizawa T, Furukawa T, Komatsu M, Ikeda R, Suzuki H, Hirota K, Aikou T, and Akiyama SI.\* Reversal of P-glycoprotein and multidrug-resistance protein-mediated drug resistance in KB cells by 5-O-benzoylated taxinine K. *Mol Pharmacol*, *58:* 1563-9, 2000. (IF: 4.5)

29 Kobayashi J, Shigemori H, Hosoyama H, **Chen ZS**, Akiyama S. Naito M, and Tsuruo T.\* Multidrug resistance reversal activity of taxoids from Taxus cuspidata in KB-C2 and 2780AD cells. *Jap J Cancer Res*, *91:* 638-42, 2000. (IF: 3.77)

28 Ren XQ, Furukawa T, **Chen ZS**, Okumura H, Aoki S, Sumizawa T, Tani A, Komatsu M, Mei X D, and Akiyama S.\* Functional comparison between YCF1 and MRP1 expressed in Sf21 insect cells. *Biochem Biophysics Res Commu*, *270:* 608-15, 2000. (IF: 2.9)

27 Komatsu M, Sumizawa T, Mutoh M, **Chen ZS**, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T, and Akiyama S.\* Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. *Cancer Res,* *60:* 1312-16, 2000. (IF: 7.7)

26 Mei X,\* Bao M, Xia H, **Chen ZS**, Ren XQ, Akiyama SI.\* Reversal Effect of Dipyridamole on KB Carcinoma Cells in Vitro. *J Cancer Prev Treat*, 14: 315-20, 2000.

**1999 (9)**

25 **Chen ZS**, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, and Akiyama SI.\* Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. *Mol Pharmacol,* *56:* 1219-28, 1999. (IF: 4.5)

24 Aoki S, Setiawan A, Yoshida Y, Higuchi K, Fudetani R, **Chen ZS**, Sumizawa T, Akiyama S, and Kobayashi M.\* Reversal of multidrug resistance in human cell line by agosterols, marine spongean sterols. *Tetrahedron*, *55:* 13965-72, 1999. (IF: 3.0)

23 Kitazono M, Sumizawa T, Takebayashi Y, **Chen ZS**, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T, and Akiyama S.\* Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. *J Nat Cancer Inst,* *91:* 1647-53, 1999. ((IF: 14.5)

22 Akiyama S,\* **Chen ZS**, Kitazono M, Sumizawa T, Furukawa T, and Aikou T. [Mechanisms for resistance to anticancer agents and the reversal of the resistance]. Human Cell, *12:* 95-102, 1999.

21 Kawabe T, **Chen ZS**, Wada M, Uchiumi T, Ono M, Akiyama S, and Kuwano M.\* Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett, *456:* 327-31, 1999. ((IF: 4.7)

20 Akiyama S,\* **Chen ZS**, and Furukawa T. Expression of P-glycoprotein and MRP in human tumors. The Best New Med (Japanese), *54:* 382-9, 1999.

19 **Chen ZS**, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, and Akiyama SI.\* ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol, *55:* 921-8, 1999. (IF: 4.5)

18 **Chen ZS**, Sumizawa T, Furukawa T, Ono K, Tani A, Komatsu M, and Akiyama SI\*. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. Cancer Lett, *138:* 13-22, 1999. (IF: 4.3)

17 Akiyama S,\* **Chen ZS,** Sumizawa T, and Furukawa T. Resistance to cisplatin. Anticancer Drugs and Designs, *14:* 143-51, 1999.

**1998 (6)**

16 Nagayama S, **Chen ZS**, Kitazono M, Takebayashi Y, Niwa K, Yamada K, Tani A, Haraguchi M, Sumizawa T, Furukawa T, Aikou T, and Akiyama SI.\* Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. Cancer Lett, *130:* 175-82, 1998. (IF:4.3)

15 Chuman Y**, Chen ZS**, Seto K, Sumizawa T, Furukawa T, Tani A, Haraguchi M, Niwa K, Yamada, K, Aikou T, and Akiyama S.\* Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Lett, *129:* 69-76, 1998. (IF: 4.3)

14. Aoki S, Yoshida Y, Miyamoto Y, Higuchi K, Setiawan A, Murakami N, **Chen ZS**, Sumizawa T, Akiyama S, and Kobayashi M.\* Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of *spongia* SP. Tetrahedron Lett, *39:* 6303-6, 1998. (IF: 3.0)

13. **Chen ZS**, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A, Saijo N, Kondo T, and Akiyama SI.\* An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. Exp Cell Res, *240:* 312-20, 1998. (IF: 3.7)

12. Akiyama S,\* Furukawa T, Sumizawa T, Tani A, and **Chen ZS.** Reversing drug resistance: Cyclosporins. Med Pharmacol J (Japanese), *34:* 107-11, 1998.

11. Furukawa T, **Chen ZS**, Sumizawa T, and Akiyama S.\* The mechanism of anticancer-drug resistance: cisplatin. Med Pharmacol J, *34:* 66-72, 1998.

**1997 (3)**

10. Sumizawa T, **Chen ZS**, Chuman Y, Seto K, Furukawa T, Haraguchi M, Tani A, Shudo N, and Akiyama SI.\* Reversal of multidrug resistance-associated protein-mediateddrug resistance by the pyridine analog PAK-104P. Mol Pharmacol, *51:* 399-405, 1997. (IF: 4.5)

9. **Chen ZS**, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A, and Akiyama S.\* Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells. Biochem Biophysics Res Comm, *236:* 586-90, 1997. (IF: 2.6)

8. Furukawa T, **Chen ZS**, and Akiyama S.\* [ATP-dependent glutathione conjugate export pump]. Nippon Rinsho, *55:* 1083-90, 1997.

**1996 (1)**

7. Chuman Y, **Chen ZS,** Sumizawa T, Furukawa T, Haraguchi M, Takebayashi Y, Niwa K, Yamada K, Aikou T, and Akiyama S.\* Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells. Biochem Biophysics Res Comm, *226:* 158-65, 1996. (IF: 2.6)

**1995 (1)**

6. **Chen ZS**, Lin JY, Xu HJ, Lu LX, and Cai W. Evaluation of the effects of QZJ-air filtrator,. Chin J Disinfect, *12:* 3-4, 1995.

**1994 (1)**

5. Fujii R, Mutoh M, Sumizawa T, **Chen ZS**, Yoshimura A, and Akiyama S.\* Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells. J Nat Cancer Inst, *86:* 1781-84, 1994. (IF: 14.6)

**1993 (1)**

4. Lin JY, **Chen ZS**, and Cai W. Studies on the "Evaluational standards of toxicological test

for cosmetics". Health Anti-epidemic J Guang Dong Province, *70:* 12-5, 1993.

**1990 (3)**

3. **Chen ZS**, and Zhou JL. Study on the interactions between glutathione, glutathione-associate enzymes and white phosphorus poisoning. J Hygiene Toxicol, *4:* 18-20, 1990.

2. **Chen ZS,** Chen QM, Yuan RT, Zheng XY, and Zhao RH. Investigation of fulminant epidemic acromelalgia in the high school students of Lian-Ping Prefecture. Health Anti-epidemic J Guang Dong Province, *61:* 21-4, 1990.

1. **Chen ZS,** Cai W, Xu HJ, Lu LX, and Lin JY. Toxicological studies of Mie Yi Lin (cyclopentadiene), Health Anti-epidemic J Guang Dong Province, *59:* 45-7, 1990.

***Publications*** (Refereed Conferences and Invited speakers)

**2016**

179. A next generation inhibitors to reverse ABCB1 transport mediated multidrug resistance in cancer

Anna Maria Barbuti, Bhargav Patel, Yi-Jun Wang, Tanaji T. Talele, Zhe-Sheng Chen.

107th American Association for Cancer Research (AACR), April 16-20, 2016, New Orleans, LA.

178. Modulation of the function of the multidrug resistance-linked ABCG2 transporter by tyrosine kinases

receptor inhibitor cabozantinib.Guan-Nan Zhang, Yun-Kai Zhang, Yi-Jun Wang, Zhe-Sheng Chen.

107th American Association for Cancer Research (AACR), April 16-20, 2016, New Orleans, LA.

177. Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of

doxorubicin. Yi-Jun Wang, Yujian Huang, Nagaraju Anreddy, Guan-Nan Zhang, Yun-Kai Zhang,

Meina Xie, Derrick Lin, Dong-Hua Yang, Mingjun Zhang\*, Zhe-Sheng Chen\* 107th American

Association for Cancer Research (AACR), April 16-20, 2016, New Orleans, LA.

176.Strategies for Overcoming Multidrug Resistance in Cancer. Zhe-Sheng Chen. **Invited**

**Speaker** in Florida Atlantic University (FAU)'s Center for Molecular Biology and Biotechnology

(CMBB) Seminar Series, April 6, 2016, Palm Beach, FL, USA.

175.Tea nanoparticle potentiates the anticancer activity of doxorubicin, Zhe-Sheng Chen. **Invited**

 **speaker** in Ohio State University, Jan. 10-12, 2016, Columbus, OH, USA.

**2015**

174. Glycolysis and Cancer, Zhe-Sheng Chen. **Invited speaker** in World Traditional Chinese Medical

 Union Anti-metabolic Diseases meeting, Nov. 27-28, 2015. Guangzhou, China

173. How to write and submit SCI articles, Zhe-Sheng Chen. **Invited speaker** in Guangdong

 Pharmaceutical University, Nov. 23, 2015, Guangzhou, China

172. How to write and submit SCI articles, Zhe-Sheng Chen. **Invited speaker** in Guangdong

 Occupational Disease Hospital, Nov. 23, 2015, Guangzhou, China

171.Reversal of MDR by motesanib (AMG706), a potent multikinase inhibitor, in cancer cells.

 Zhe-Sheng Chen. **Invited speaker** in Weifang Medical University, Nov. 20, 2015, Weifang, China

170.Reversal of multidrug resistance by tyrosine kinase inhibitors in cancer. Zhe-Sheng Chen.

 **Invited speaker** in Sichuang University, Nov. 10, 2015, Chengdu, China

169.Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through

a novel BCR-ABL inhibitor. Zhe-Sheng Chen. **Invited speaker** in the 4th Guangzhou International Symposium on Oncology, Nov. 5-7, Guangzhou, China

168. How to write and submit SCI articles, Zhe-Sheng Chen. **Invited speaker** in Jinan University,

 Aug. 27, 2015, Guangzhou, China

167. Overcoming multidrug resistance in cancer. Zhe-Sheng Chen. **Invited speaker** in Henan

Hospital, Aug. 26, 2015, Guangzhou, China

166.Spiroisobenzofuranone derivatives as potential anticancer agents. Chen Yin, Peng-jen Chen,

Zhe-Sheng Chen, Ralph Stephani, Vijaya L. Korlipara. Poster, 250th American Chemical Society

National meeting and Exposition, Aug. 16-20, 2015, Boston, MA, USA.

165. Design, synthesis and biological evaluation of bioisosteric analogues of dasatinib as Src, Abl and

 Abl T315I protein tyrosine kinase inhibitors. Jay Patel, Zhe-Sheng Chen and Vijaya L.

 Korlipara. Poster, 250th American Chemical Society National meeting and Exposition, Aug. 16-20,

 2015, Boston, MA, USA.

164. Overcoming multidrug resistance in cancer. Zhe-Sheng Chen. **Invited speaker** in Yichang Central

 Hospital, Aug. 15, 2015, Yichang, China

163. Overcoming multidrug resistance in cancer. Zhe-Sheng Chen. **Invited speaker** in Huazhong

 University of Science and Technology, Aug. 14, 2015, Wuhan, China

162. Reversal of multidrug resistance by tyrosine kinase inhibitors and PDE5 inhibitors in cancer.

Zhe-Sheng Chen. **Invited speaker** in Southwest Jiaotong University, Aug. 10, 2015, Chengdu,

China

161.Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through

 a novel BCR-ABL inhibitor. Zhe-Sheng Chen. **Invited speaker** in Fudan Cancer Hospital,

 Aug. 7, 2015, Shanghai, China

160.Reversal of multidrug resistance by tyrosine kinase inhibitors and PDE5 inhibitors in cancer.

Zhe-Sheng Chen. **Invited speaker** in Henan People’s Hospital, July 29, 2015, Zhengzhou,

China

159.Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through

 a novel BCR-ABL inhibitor. Zhe-Sheng Chen. **Invited speaker** in Zhengzhou University,

 July 28, 2015, Zhengzhou, China

158. Reversal of MDR by Motesanib (AMG706), a potent multikinase inhibitor, in cancer cells.

 Zhe-Sheng Chen. **Invited speaker** in Hunan University, July 21, 2015, Zhengzhou, China

157.Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through

 a novel BCR-ABL inhibitor. Zhe-Sheng Chen. **Invited speaker** in Jinan University,

 July 13, 2015, Guangzhou, China

156.Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through

 a novel BCR-ABL inhibitor. Zhe-Sheng Chen. **Invited speaker** in Weifang Medical University,

 July 7, 2015, Weifang, China

155. Reversal of multidrug resistance by tyrosine kinase inhibitors and PDE5 inhibitors in cancer.

Zhe-Sheng Chen. **Invited speaker** in Qingdao Agriculture University, July 6, 2015, Qingdao,

China

154.Reversal of multidrug resistance by tyrosine kinase inhibitors and PDE5 inhibitors in cancer.

Zhe-Sheng Chen. **Invited speaker** in Guangxi Medical University, June 29, 2015, Nanning, China

153**.** Reversal of multidrug resistance by tyrosine kinase inhibitors Zhe-Sheng Chen. **Invited speaker**

 at Jiangxi Science and Normal University, June 4, 2015.

152.Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through

 a novel BCR-ABL inhibitor. Zhe-Sheng Chen. **Invited speaker** at Sun Yat-Sen University, College

 of Chemistry and Chemical Engineering, June 3, 2015.

151. Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through

 a novel BCR-ABL inhibitor. Zhe-Sheng Chen. **Invited speaker** at Southern Medical University,

 May 23, 2015.

150.(20S, 24R/S)‐epoxy‐ 12ß,25‐dihydroxy‐ dommarane‐3ß‐amine, novel semi‐synthetic ocotillol

 analogues, reverse ABCB1‐mediated drug resistance. Yun-Kai Zhang, Heng-Yuan Zhang, Jin-Yi Xu

 and Zhe-Sheng Chen, Poster, Multi-Drug Efflux Systems, A Paradigm Shift from Fundamental

 Mechanisms to Practical Applications, Renaissance Tuscany Il Ciocco Lucca (Barga), Gordon

 Research Conference-Italy, April 26 - May 1, 2015.

149. TTT-28, a newly synthesized thiazole-valine peptide, antagonizes multidrug resistance by inhibiting

 the efflux activity of the ABCB1 transporter. Yi-Jun Wang, Nagaraju Anreddy, Bhargav A. Patel,

 Eduardo E. Chufan, Satyakam Singh, Guan-Nan Zhang, Yun-Kai Zhang, Anna Maria Barbuti, Suresh

V. Ambudkar, Tanaji T. Talele, Zhe-Sheng Chen. 106th American Association for Cancer Research

(AACR), April 18-22, 2015, Philadelphia, PA.

148. Design, synthesis and biological evaluation of N-aryl-3,3,3-triﬂuoro-2-hydroxy-2-

 methylpropionamide analog as a promising inhibitor of the multidrug resistance-linked ABCG2

 transporter. Atish S. Patel, Tianwen Li, Nagaraju Anreddy, Yufen Zhao, Rishil J. Kathawala,

 Yijun Wang, Suresh V. Ambudkar, Zhe-Sheng Chen, Changmei Cheng. 106th American

 Association for Cancer Research (AACR), April 18-22, 2015, Philadelphia, PA.

147. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in

 vitro and in vivo. Nagaraju Anreddy, Atish Patel, Yun-Kai Zhang, Yi-Jun Wang, Suneet Shukla,

 Rishil J. Kathawala, Priyank Kumar, Pranav Gupta, Suresh V. Ambudkar, John ND Wurpel, Zhe-

 Sheng Chen**.** 106th American Association for Cancer Research (AACR), April 18-22, 2015,

Philadelphia, PA.

146. Lapatinib promotes promoted the incidence of hepatotoxicity by increasing chemotherapeutic agent

accumulation in hepatocytes. Chunling Dai, Shaolin Ma, Zhe-Sheng Chen, Kenneth To, Liwu Fu.

106th American Association for Cancer Research (AACR), April 18-22, 2015,

Philadelphia, PA.

**2014**

145**.** Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance

mediated by thymidylate synthase and ABCG2, Zhe-Sheng Chen. **Invited speaker** in Sun-Yat-Sen University Medical School, Oct.23, 2014, Guangzhou, China.

144.Reversal of multidrug resistance by tyrosine kinase inhibitors and PDE5 inhibitors in cancer.

Zhe-Sheng Chen. **Invited speaker** in Sun Yat-Sen University Xinhua College, Oct 22,

2014, Guangzhou, China

143.Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance

mediated by thymidylate synthase and ABCG2, Zhe-Sheng Chen. **Invited speaker** 3rd Congress on Advances in Personalized Chemotherapy for Cancer and Anticancer Drug Research, Oct 18-19, 2014, Shenzhen, China.

142. Bestinib, a novel Bcr-Abl inhibitor for Chronic Myeloid Leukemia, inhibits a wide array of Bcr-Abl mutants including imatinib-resistant T315I mutant. Gupta P, Yang K, Wang F, Wang X, Kathawala RJ,Fu LW and Chen ZS. **Plenary Talk** at the 19th World Congress on Advances in Oncology and 17th Inter-national Symposium on Molecular Medicine, Oct 09-11, 2014, Athens, Greece.

141. The reversal of ABCG2-mediated multidrug resistance (MDR) by PD153035, an inhibitor of the epidermal growth factor receptor tyrosine kinase: an *in vitro* study. Zhang GN, Zhang YK, Kathawala RJ**,** Wang YJ, Ashby CR, and Chen ZS. **Plenary Talks** at the 19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, Oct 09-11, 2014, Athens, Greece.

140.Synthesis and biological evaluation of ocotillol analogues as P-glycoprotein inhibitors. Hengyuan

Zhang, Yunkai Zhang, Zhiwen Zhou, Xiaoming Wu, Zhe-Sheng Chen, Jinyi Xu, 2014’ Yangtze River

Delta Symposium on Medicinal Chemistry. Sept. 28-29, 2014, Shanghai, China.

139.Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance

mediated by thymidylate synthase and ABCG2, Zhe-Sheng Chen. **Invited speaker** Cancer

Institute and Hospital, Chinese Academy of Medical Sciences, July 28, 2014, Beijing, China.

138. Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance

mediated by thymidylate synthase and ABCG2, Zhe-Sheng Chen. **Invited speaker** National

Nano Center, July 18, 2014, Beijing, China.

137. Reversal of MDR by Tyrosine kinase inhibitors. Zhe-Sheng Chen. **Invited speaker** atCollege of Chemistry and Chemical Engineering, Sun Yat-Sen University, June 9,, 2014, Guangzhou, China.

136. Reversal of MDR by Tyrosine kinase inhibitors. Zhe-Sheng Chen. **Invited speaker** atGuangdong Pharmaceutical University, June 9,, 2014, Guangzhou, China.

135. Masatinib Reverses ABCC10-Mediated MDR. Zhe-Sheng Chen. **Invited speaker** atGuangdong Industrial University, June 6, 2014, Guangzhou, China.

134. Reversal of MDR in Cancer. Zhe-Sheng Chen. **Invited speaker** atCollege of Medicine, Sun-Yat-Sen University, June 4, 2014, Guangzhou, China.

133. Reversal of MDR in Cancer. Zhe-Sheng Chen. **Invited speaker** atSun Yat-Sen Hospital, June 3, 2014, Guangzhou, China.

132. ABC Transporter and MDR in Cancer. Zhe-Sheng Chen. **Invited speaker** at 6th International Symposium on Bioanalysis, Biomedical Engineering and Nanotechnology, May 28-31, 2014, Changsha, China.

131. Reversal of ABC Transporter-mediated MDR by PDE5 inhibitors and tyrosine kinase inhibitors. Zhe-Sheng Chen. **Invited speaker** at College of Pharmacy, Zhengzhou University, June 2, 2014, Zhengzhou, China.

130. Reversal of ABC Transporter-mediated MDR by Masitinib. Zhe-Sheng Chen. **Invited speaker** at Jinan University, College of Life Science and Technology, May 22, 2014, Guangzhou, China.

129. Reversal of ABC Transporter-mediated MDR by Masitinib. Zhe-Sheng Chen. **Invited speaker** at College of Pharmacy, Weifang Medical School, May 20, 2014, Weifang, China.

128. Reversal of ABC Transporter-mediated MDR by PDE5 inhibitors and tyrosine kinase inhibitors. Zhe-Sheng Chen. **Invited speaker and Chair** at BIT’s World Cancer Congress, May 18, 2014, Nanjing, China.

127. Reversal of ABC Transporter-mediated MDR by Masitinib. Zhe-Sheng Chen. **Invited speaker** at College of Pharmacy, Nanjing Medical University, May 17, 2014, Nanjing, China.

126. Reversal of ABC Transporter-mediated MDR by PDE5 inhibitors and tyrosine kinase inhibitors. Zhe-Sheng Chen. **Invited speaker** at Shuguan Hospital, Shanghai University of Traditional Chinese Medicine, May 16, 2014, Shanghai, China.

125. Reversal of ABC Transporter-mediated MDR by Masitinib. Zhe-Sheng Chen. **Invited speaker** at Tumor Hospital, Fudan University, May 15, 2014, Shanghai, China.

124. Masitinib antagonizes ATP-binding cassette subfamily c member 10-mediated paclitaxel resistance: a preclinical study. Rishil Kathawala, Kamlesh Sodani, Kang Chen, Atish Patel, Alaa Abuznait, Nagaraju Anreddy, Yue-Li Sun, Amal Kaddoumi, Charles R. Ashby, Jr., Zhe-Sheng Chen. 105th American Association for Cancer Research (AACR), April 5-9, 2014, San Diego, CA.

123. Suppression of ABCG2 mediated MDR *in vitro* and *in vivo* by a novel inhibitor of ABCG2 transport. Atish S. Patel., Zhe-Sheng Chen, 105th American Association for Cancer Research (AACR), April 5-9, 2014, San Diego, CA.

122. A-803467, a sodium channel blocker, reverses ABCG2-mediated MDR. Nagaraju Anreddy,

Atish Patel, Rishil J kathawala, John N. D Wurpel, Zhe-Sheng Chen, 105th American Association for Cancer Research (AACR), April 5-9, 2014, San Diego, CA

**2013**

121 Quizartinib (AC220) potentiates the antineoplastic activity of wild-type ABCG2 and ABCB1 substrates. Priyank Kumar, Rishil J. Kathawala, Hui Zhang, Nagaraju Anreddy, Yanglu Chen, Kanav Gupta, Louis D. Trombetta and Zhe-Sheng Chen. Poster at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19-23, 2013, Boston, MA.

120. Icotinib (BPI-2009H) reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2. De-Shen Wang, Atish Patel, Rishil J. Kathawala, Hui Zhang, Priyank Kumar, Yun-Kai Zhang, Nagaraju Anreddy, Rui-hua Xu, Zhe-Sheng Chen. **Oral presentation** at 10th North American ABC Workshop. Sept. 19-20, 2013, NCI-Frederick, Maryland.

119.Motesanib, a potent multikinase inhibitor, reverses ABCB1- and ABCG2-mediated drug resistance in cancer cells. Yi-Jun Wang, Rishil J. Kathawala, Yun-Kai Zhang, Kamlesh Sodani, Atish Patel, Priyank Kumar, Tanaji T. Talele, Zhe-Sheng Chen, **Oral presentation** at 10th North American ABC Workshop. Sept. 19-20, 2013, NCI-Frederick, Maryland.

118.Suppression of ABCG2 mediated MDR *in vitro* and *in vivo* by a novel inhibitor of ABCG2 transport. Atish Patel**,** Nagaraju Anreddy, Tianwen Li, Kamlesh Sodani, Guannan Zhang, Changmei Chang, Zhe-Sheng Chen. **Best Poster Award** at 10th North American ABC Workshop. Sept. 19-20, 2013, NCI-Frederick, Maryland.

117.β-Elemene, a compound derived from *Rihizoma zedoariae*, reverses multidrug resistance mediated by ABCB1 transporter. Guan-Nan Zhang, Hui-Qin Guo, Yi-Jun Wang, Yun-Kai Zhang, Kamlesh Sodani, Tanaji T. Talele, Charles R. Ashby Jr, Zhe-Sheng Chen. **Poster** at 10th North American ABC Workshop. Sept. 19-20, 2013, NCI-Frederick, Maryland.

116.Ibrutinib (PCI-32765) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Hui Zhang, Yunkai Zhang, Guannan Zhang, Priyank kumar, Li-wu Fu, Zhe-Sheng Chen. **Poster** at 10th North American ABC Workshop. Sept. 19-20, 2013, NCI-Frederick, Maryland.

115.Enhancing Chemosensitivity in ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-Like Cells by An Aurora Kinase Inhibitor CCT129202. Chao Cheng, Zhen-guo Liu, Hui Zhang, Fo-tian Zhong, Fang Wang, Yong-ju Liang, Li-kun Chen, Satyakam Singh, Jun-jiang Chen, Tanaji T. Talele, Zhe-Sheng Chen, Li-wu Fu. **Poster** at 10th North American ABC Workshop. Sept. 19-20, 2013, NCI-Frederick, Maryland.

114.Reversal of multidrug resistance by tyrosine kinase inhibitors and PDE5 inhibitors in cancer. Zhe-Sheng Chen. **Invited speaker** in International Forum of Basic and Clinical study on Anti-tumor Pharmacy, June 6-8, 2013, Changsha, China

113.Reversal of BCRP-mediated MDR in cancer, Zhe-Sheng Chen. **Invited speaker** Jinan University School of Pharmacy, June 5, 2013, Guangzhou, China.

112.Reversal of BCRP-mediated MDR in cancer, Zhe-Sheng Chen. **Invited speaker** South China Medical University School of Pharmacy, June 5, 2013, Guangzhou, China.

111.Reversal of BCRP-mediated MDR in cancer, Zhe-Sheng Chen. **Invited speaker** Shantou University Medical School, June 3, 2013, Shantou, China.

110.Telatinib is a potent reversal agent for reversing BCRP-mediated MDR in cancer, Zhe-Sheng Chen. **Invited speaker** University of Macau, May 30, 2013, Macau, China.

109.Bringing International Scholars to Campus in USA. Zhe-Sheng Chen. **Invited speaker,** Sun-Yat-Sen University, School of Chemistry and Chemical Engineering, May 29, 2013, Guangzhou, China.

108.Bringing International Scholars to Campus in USA. Zhe-Sheng Chen. **Invited speaker,** Guangzhou Medical University, May 28, 2013, Guangzhou, China.

107.Telatinib is a potent reversal agent for reversing BCRP-mediated MDR in cancer, Zhe-Sheng Chen. **Invited speaker** GuangdongUniversity of Technology, May 24, 2013, Guangzhou.Chnia.

106.Reversal of MDR by Tyrosine kinase inhibitors in cancer, Zhe-Sheng Chen. **Invited speaker** Foshan First People’s Hospital, May 23, 2013, Foshan, China

105.Regulation of P-gp in blood brain barrier and epileptic disease treatment. Zhe-Sheng Chen. **Invited speaker** Guangdong Center for Disease Contral and Prevention, May 23, 2013, Guangzhou, China

104.PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Atish S. Patel, Amit Tiwari, Eduardo Chufan, Satyakam Singh, Kamlesh Sodani, Nagaraju Anreddy, Tanaji Talele, Suresh Ambudkar, Ralph Stephani, and Zhe-Sheng Chen. 104th American Association for Cancer Research (AACR), April 6~10, 2013, Washington D.C.

103.Sildenaﬁl potentiates the anticancer activity of paclitaxel in ABCB1-mediated multidrug resistance xenograft model. Kamlesh Sodani, Amit K. Tiwari, Chunling Dai, Alaa H. Abuznait, Zhi-jie Xiao, Amal Kaddouni, and Zhe-Sheng Chen. 104th American Association for Cancer Research (AACR), April 6~10, 2013, Washington D.C.

**2012**

102.Nilotinib potentiates anticancer sensitivity in murine multidrug resistance xenograft models. Kamlesh Sodani, Amit K Tiwari, Priyank Kumar, Chun-ling Dai, Satyakam Singh, Alaa H. Abuznait, Zhi-Jie Xiao, Saurabh Vispute, Atish Patel, Tanaji Talele, Amal Kaddoumi, James M. Gallo, and Zhe-Sheng Chen. **Oral presentation** at 9th North American ABC workshop. Sept. 27-28, 2012, NCI-Frederick, Maryland.

101.Vemurafenib, a BRAF enzyme inhibitor, modulates ABCB1-, ABCG2-, and ABCC10-mediated multidrug resistance. Saurabh G. Vispute, Jun-Jiang Chen, Yue-Li Sun, Kamlesh Sodani, Satyakam Singh, Tanaji T., Talele, Zhe-Sheng Chen and Charles R. Ashby Jr. **Oral presentation** at 9th North American ABC workshop. Sept. 27-28, 2012, NCI-Frederick, Maryland.

100.Masitinib (AB1010) antagonizes multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transporters ABCB10 and ABCG2. Rishil J. Kathawala, Yue-Li Sun, Jun-Jiang Chen, Kang Chen, Chun-Ling Dai, Zhe-Sheng Chen and Charles R. Ashby Jr. **Oral presentation** at 9th North American ABC workshop. Sept. 27-28, 2012, NCI-Frederick, Maryland.

99. AV-951 reverses multidrug resistance by inhibiting ABCB1(P-gp) and ABCG2 (BCRP) Activity. Dan-Wen Yang, Xiang Chen, Rishil J. Katawala, Atish Patel, Kamlesh Sodani, Yui-Li Sun, Jun-Jiang Chen, and Zhe-Sheng Chen. **Oral presentation** at 9th North American ABC workshop. Sept. 27-28, 2012, NCI-Frederick, Maryland.

98. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** in 2nd Congress on Advances in Personalized Chemotherapy for Cancer and Anticancer Drug Research, July 14-15, 2012, Shenzhen, China.

97. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** at Xuehe Hospital Cancer Center, Huazhong University of Technology, July 12, 2012, Wuhan, China.

96. Drug Resistant mechanisms of heavy metals in the arsenic trioxide resistant cancer cells. Zhe-Sheng Chen, **Invited speaker** at Central South University, July 10, 2012, Changsha, China

95. Drug Resistant mechanisms of heavy metals in the arsenic trioxide resistant cancer cells. Zhe-Sheng Chen, **Invited speaker** at Sun Yat-Sen University Cancer Center, July 9, 2012, Guangzhou, China.

94. Drug Resistant mechanisms of heavy metals in the arsenic trioxide resistant cancer cells. Zhe-Sheng Chen, **Invited speaker** at Guangdong General Hospital, July 2, 2012, China.

93. Drug Resistant mechanisms of heavy metals in the arsenic trioxide resistant cancer cells. Zhe-Sheng Chen, **Invited speaker** at Guangxi Normal University, June 29, 2012, Guilin, China.

92. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** at Guilin Medical University, June 28, 2012, Guilin, China.

91. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** at Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, June 27, 2012, Guangzhou, China.

90. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** at Guangdong Center for Disease Control and Prevention, June 26, Guangzhou, China.

89. Bilingual Education Lecture at Guangzhou Medical University, June 15, 2012, Guangzhou, China.

88. Drug Resistant mechanisms of heavy metals in the arsenic trioxide resistant cancer cells. Zhe-Sheng Chen, **Invited speaker** at Sun Yat-Sen University School of Chemistry and Chemical Enginering, June 8, 2012, Guangzhou, China.

87. Drug Resistant mechanisms of heavy metals in the arsenic trioxide resistant cancer cells. Zhe-Sheng Chen, **Invited speaker** at Department of Chemistry, University of Science and Technology of China, June 5, 2012, Hefei, China.

86. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** at Huaiying College of Technology, School of Life Science and Chemical Engineering, June 4, Huai’an, China.

85. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** at Fudan University Tumor Hospital, June 1, Shanghai, China.

84. Drug Resistant mechanisms of heavy metals in the arsenic trioxide resistant cancer cells. Zhe-

 Sheng Chen, **Invited speaker** at Guangzhou Medical University first Affiliated Hospital, May

 31, 2012, Guangzhou, China.

83. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** at Chinese Medical University, May 20, 20102, Shenyang, China.

82. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** at National Center for Nanoscience and nanotechnology, May 18, 20102, Beijing, China.

81. Potential for anticancer treatment from non-anticancer clinical used drugs. Zhe-Sheng Chen. **Invited speaker** at School of Pharmacy, Peking University, May 18, 20102, Beijing, China.

80. Drug Resistant mechanisms of heavy metals in the arsenic trioxide resistant cancer cells. Zhe-Sheng Chen, **Invited speaker** at Jinan University College of Pharmacy, May 11, 2012, Guangzhou, China.

79. Protective mechanisms of heavy metals in the arsenic trioxide resistant cancer cells. Zhe-Sheng Chen, **Invited speaker** at Guangdong Pharmaceutical University, May 9, 2012, Guangzhou, China.

78. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2, Wen Deng, Chun-Ling Dai, Xiao-qin Zhao, Shinobu Ohnuma, Yong-ju Liang, Zhi-Jie Xiao, Mu-Sheng Zeng, Suresh V. Ambudkar, Li-Wu Fu, and Zhe-Sheng Chen. 103rd American Association for Cancer Research (AACR), March 31~April 4, 2012, Chicago, IL.

77. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance, Kamlesh S. Sodani, Amit K. Tiwari, Satyakam Singh, Atish Patel, Zhijie Xiao, Junjiang Chen, Yueli Sun, Tanaji T. Talele, Zhe-Sheng Chen. 103rd American Association for Cancer Research (AACR), March 31~April 4, 2012, Chicago, IL.

76. PDE5 inhibitors as reversal agents for enhancing cancer chemotherapeutic effects. Zhe-Sheng Chen. Invited speaker, City College of CUNY, Department of Chemistry, Biochemistry Seminar, March 14, 2012, New York, NY.

75.Screening for compounds that reverse MRP7-mediated multidrug resistanceZhe-Sheng Chen, Yueli Sun, Wen Deng, Junjiang Chen, Rishil Kathawala, Yehong Kuang, Tong Shen, Amit K. Tiwari, Charles R. Ashby Jr.,Liwu Fu, Chunling Dai. FEBS-ABC2012 - 4th FEBS Special Meeting on ABC Proteins, March 3-9, 2012, Innsbruck, Austria.

**2011**

74. B2B1, one of 23-hydroxybetulinic acid analogs, can modulate ABC transporters mediated MDR. Jun-Jiang Chen, Dong-Mei Zhang, Jaya Bhatnagar, Amit K. Tiwari, Wei-Min Chen, Suresh V. Ambudkar, Si-Dong Chen, Wen-Cai Ye, and Zhe-Sheng Chen. **Oral presentation** at 8th North American ABC workshop. Sept. 28-29, 2011, NCI-Frederick, Maryland.

73.XR9576 (Tariquidar) is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance. Yueli Sun, Jung-Jiang Chen, Wen Deng, Zhijie Xiao, Rishil Kathawala, Priyank Kumar, Kamlesh Sodani, Si-Dong-Chen, Wenqi Jiang, and Zhe-Sheng Chen. **Oral presentation** at 8th North American ABC workshop. Sept. 28-29, 2011, NCI-Frederick, Maryland.

72.PD173074, a selective FGFR1 and FGFR3 inhibitor, reverses ABCB-1-mediated multidrug resistance. Atish Patel, Amit K. Tiwari, Kamlesh Sodani, Satyakam Singh, Saraubh Vispute, Zhe-Sheng Chen, Tanaji Talele, and Ralph Stephani. **Oral presentation** at 8th North American ABC workshop. Sept. 28-29, 2011, NCI-Frederick, Maryland.

71.Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2 (ABCG2)**.** Wen Deng, Chun-ling Dai, Xiao-qin Zhao, Shinobu Ohnuma, Yong-ju Liang, Mu-sheng Zeng, Suresh V. Ambudkar, Zhe-Sheng Chen, and Li-wu Fu. Poster at 8th North American ABC workshop. Sept. 28-29, 2011, NCI-Frederick, Maryland.

10.PDE5 inhibitors as modulators of ABC transporter mediated multidrug resistance in cancer. Zhe-Sheng Chen. **Invited speaker** at RayBiotech. Co, Aug. 1st, 2011, Atlanta.

69.PDE5 inhibitors as modulators of ABC transporter mediated multidrug resistance in cancer. Zhe-Sheng Chen. **Invited speaker** at Gordon Research Conference-Multi-Drug Efflux Systems, June 12-17, 2011, Les Diablerets, Switzerland.

68.PDE5 inhibitors reverse ABCB1- and ABCG2-mediated chemotherapeutic drug resistance in cancer. Zhe-Sheng Chen. **Invited speaker** at Sun Yat-Sen University College of Pharmacy, June 1st, Guangzhou, China.

67.PDE5 inhibitors reverse ABCB1- and ABCG2-mediated chemotherapeutic drug resistance in cancer. Zhe-Sheng Chen. **Invited speaker** at Jinan University College of Pharmacy, May 31st, Guangzhou, China.

66.PDE5 inhibitors reverse ABCB1- and ABCG2-mediated chemotherapeutic drug resistance in cancer. Zhe-Sheng Chen. **Keynote speaker** at the 2nd Guangzhou International Symposium on Oncology, May 21-22, Guangzhou, China.

65.PDE5 inhibitors reverse ABCB1- and ABCG2-mediated chemotherapeutic drug resistance in cancer. Zhe-Sheng Chen. **Invited speaked** at Guangdong Pharmaceutical University, May 20, 2011, Guangzhou, China.

64.Reversal of ABCB1- and ABCG2-mediated drug resistance by sildenafil. Amit K. Tiwari, Zhi Shi, Suneet Sgukla, Robert W. Robey, Satyakam Singh, In-Wha Kim, Susan E. Bates, Xing-Xiang Peng, Ioana Abraham, Suresh V. Ambudkar, Tanaji T. Talele, Li-wu Fu, and Zhe-Sheng Chen. 102nd American Association for Cancer Research (AACR), April 1~6, 2011, Orlando, FL.

63.Analog of OSI-930 as potent ABCG2-mediated multidrug resistance reversal agents. Jay P. Patel, Yehong Kuang, Kamlesh Sodani, Chun-Pu Wu, Li-Qiu Liao, Amit K. Tiwari, Chun-ling Dai, Xiang Chen, Li-wu Fu, Suresh V. Ambudkar, Vijaya L. Korlipara, and Zhe-Sheng Chen. 102nd American Association for Cancer Research (AACR), April 1~6, 2011, Orlando, FL.

**2010**

62.PDE inhibitors as new MDR modulators. Amit Tiwari, Zhi Shi, Peirong Ding, Zhe-Sheng Chen. **Oral presentation** at 7th North American ABC workshop. Sept. 14-55, 2010, NCI-Frederick, Maryland.

61.Analogues of OSI-930, a novel dual c-kit and KDR tyrosine kinase inhibitor, reverse ABCG2-mediated multidrug resistance. Kamlesh Sodani, Ye-Hong Kuang, Jay Patel, Chun-Pu Wu, Li-Qiu Liao, Amit K Tiwari, Vijaya Korlipara, Chun-ling Dai, Wen Deng, Li-Wu Fu, Xiang Chen, Suresh V Ambudkar, Zhe-Sheng Chen. **Oral presentation** at 7th North American ABC workshop. Sept. 14-55, 2010, NCI-Frederick, Maryland.

60.ABCC10 (MRP7)-mediated multidrug resistance in cancer. Zhe-Sheng Chen. **Seminar** at Central South University, Aug. 11, 2010, Changsha, China.

59.ABCC10 (MRP7)-mediated multidrug resistance in cancer. Zhe-Sheng Chen. **Invited speaker** in 1st Congress on Advances in Personalized Chemotherapy for Cancer and Anticancer Drug Research, Aug. 7-8, 2010, Guangzhou, China.

58.ABCC10 (MRP7)-mediated multidrug resistance in cancer. Zhe-Sheng Chen. **Invited speaker** at Hongkong University of Chinese, July. 30, 2010, Hongkong, China.

57.BCR-Abl tyrosine kinase inhibitor Nilotinib (Tasigna®) reverses ABCB1/Pgp- anABCG2/BCRP -mediated multidrug resistance. Amit K. Tiwari, Kamlesh Sodani, Sirong Wang, Ye-Hong Kuang, Xiang Chen, Wen Deng, Kevin Chen, Charles R. Ashby Jr., Zhe-Sheng Chen 101st American Association for Cancer Research (AACR), April 17~21, 2010, Washington D.C.

56.Sunitinib reverses ABCG2/BCRP-mediated multidrug resistance by inhibiting its efflux activity

Chun-ling Dai, Yong-ju Liang, Yan-sheng Wang, Amit K. Tiwari, Yan-yan Yan, Fang Wang, Zhe-Sheng Chen, Xiu-zhen Tong, Li-wu Fu, 101st American Association for Cancer Research (AACR), April 17~21, 2010, Washington D.C.

55.Lapatinib, erlotinib, imatinib and nilotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Kamlesh Sodani, Ye-Hong Kuang, Tong Shen, Saurabh Vispute Amit K. Tiwari, Yu Lei, Jeferson Lee, Xiang Chen, Charles R. Ashby Jr., Zhe-Sheng Chen. 101st American Association for Cancer Research (AACR), April 17~21, 2010, Washington D.C.

**2009**

54.Lapatinib, erlotinib, imatinib and nilotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Kamlesh Sodani, Ye-Hong Kuang, Tong Shen, Thomas M. D’Ambra, Amit K. Tiwari, Yu Lei, Jeferson Lee, Xiang Chen, Charles R. Ashby Jr, Zhe-Sheng Chen. **Oral presentation** at 6th North American ABC workshop. Sept. 24-25, 2009, NCI-Frederick, Maryland.

53.Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Ioana Abraham, Sandeep Jain, Chung-Pu Wu, Yehong Kuang, Zhi Shi, Xiang Chen, Wen Deng, Liwu Fu, Suresh V. Ambudkar, Khalid El Sayed, Zhe-Sheng Chen. **Oral presentation** at 6th North American ABC workshop. Sept. 24-25, 2009, NCI-Frederick, Maryland.

52.Reversal of ABCB1-mediated multidrug resistance in leukemia cells by lapatinib in vitro and ex vivo. Chun-ling Dai, Yan-Sheng Wang, Xiu-Zheng Tong, Yongju Liang, Zhe-Sheng Chen, Suresh V. Ambudkar, Susan Bates, Liwu Fu. Poster at 6th North American ABC workshop. Sept. 24-25, 2009, NCI-Frederick, Maryland.

51.Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Amit K. Tiwari, Kamlesh Sodani, Sirong Wang, Ye-Hong Kuang, Xiang Chen, Kevin Chen, Charles R. Ashby Jr., Zhe-Sheng Chen. Poster at 6th North American ABC workshop. Sept. 24-25, 2009, NCI-Frederick, Maryland.

50.ABCC10 (MRP7)-mediated multidrug resistance in cancer. Zhe-Sheng Chen. **Invited speaker**

 in LCB Seminar, Division of Basic Sciences, NCI, NIH Sept 2009, Washington D.C.

 <http://lcb.nci.nih.gov/Seminar%20schedule.html>

49.Tyrosine kinase inhibitors as modulators of MDR in cancer. Zhe-Sheng Chen. **Invited speaker**

in Peking University Institute of Molecular Medicine, July 9, 2009, Beijing, China.

48.Tyrosine kinase inhibitors as modulators of MDR in cancer. Zhe-Sheng Chen. **Invited speaker** in National Center for Nanoscience and nanotechnology, July 9, 2009, Beijing, China.

47.Tyrosine kinase inhibitors as modulators of MDR in cancer. Zhe-Sheng Chen. **Invited speaker** in National Engineering Research Center for R&D TCM Multi-ingredient Drugs, July 10, 2009, Beijing, China.

46.Tyrosine kinase inhibitors as modulators of MDR in cancer. Zhe-Sheng Chen. **Invited speaker** in Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College, July 10, 2009, Beijing, China.

45.Tyrosine kinase inhibitors as modulators of MDR in cancer. Zhe-Sheng Chen. **Invited speaker** in Central South University Xianya School of Medicine, July 13, 2009, Changsha, China.

44.Tyrosine kinase inhibitors as modulators of MDR in cancer. Zhe-Sheng Chen. **Invited speaker** in Cancer Center of Sun Yat-Sen University, July 21, 2009, Guangzhou, China.

43.Marine sponge-derived sipholane triterpenes reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Ioana Abraham, Sandeep Jain, Chung-Pu Wu, Yehong Kuang, Jefferson Kevin Lee, Xiang Chen, Khalid El Sayed, Suresh V. Ambudkar, Zhe-Sheng Chen. 100th American Association for Cancer Research (AACR), April 18~22, 2009, Denver, Colorado

42.RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Ye-Hong Kuang, Xiang Chen, Juan Su, Li-Sha Wu, Li-Qiu Liao, Dai Li, Takuro Kanekura, Zhe-Sheng Chen. 100th American Association for Cancer Research (AACR), April 18~22, 2009, Denver, Colorado

41.Lapatinib could reverse ABCB1 and ABCG2 mediated-multidrug resistance *in Vitro, ex-vivo* and *in Vivo* but increase exposure of chemotherapeutic agent. Chun-ling Dai, Yan-sheng Wang, Amit K. Tiwari, Chung-pu Wu, Xiao-dong Su, Si-rong Wang, Dong-geng Liu, Charles R. Ashby Jr., Yan Huang, Robert W. Robey, Yong-ju Liang, Li-ming Chen, Cheng-jun Shi, Suresh V. Ambudkar, Zhe-Sheng Chen, Liwu Fu. 100th American Association for Cancer Research (AACR), April 18~22, 2009, Denver, Colorado

**2008**

40.TYROSINE KINASE INHIBITORS AS MODULATORS OF MULTIDRUG RESISTANCE IN CANCER. Zhe-Sheng ChenAmit K. Tiwari, Zhi Shi, Chun-Ling Dai, Suneet Shukla, Chung-Pu Wu, Si-Rong Wang, Ioana Abraham, Kamleshkumar Sodani, Charles R. Ashby Jr, Yehong Kuang, Robert W. Robey, Li-Wu Fu, Susan E. Bates, Suresh V. Ambudkar. **Oral presentation** at **Abcam** Multidrug Resistance & ABC Transporters Conference. Nov. 5th, 2008. Baltimore, Maryland (Dr. Chen served as a committee member of “best poster award” at the Abcam conference). <http://www.abcam.com/index.html?pageconfig=resource&rid=11531&source=pagetrap>

39.Differential Effects of the EGFR Tyrosine Kinase Inhibitor AG1478 on the Function of ABCB1 and ABCG2. Amit Tiwari, Zhi Shi, Suneet Shukla, Robert W. Robey, In-Wha Kim, Susan E. Bates, Qiu-Sheng Si, Curtis S. Goldblatt, Smitaben Parmar, Ioana Abraham,Yang-Min Chen, Li-Wu Fu, Suresh V. Ambudkar, Zhe-Sheng Chen. **Oral presentation** at 5th North American ABC workshop. Sept. 24-26, 2008, NCI-Frederick, Maryland.

38.Cepharanthine Is a Potent Reversal Agent for MRP7-Mediated Multidrug Resistance. Tong Shen, Ying Zhou, Elizabeth Borge-Hopper, Xiao-Cong Huang, Zhi Shi, Tatsuhiko Furukawa, Shin-Ichi Akiyama, Kamlesh Sodani, Charles R. Ashby, Jr., Gary D. Kruh, and Zhe-Sheng Chen. **Oral presentation** at 5th North American ABC workshop. Sept. 24-26, 2008, NCI-Frederick, Maryland.

37. Reversal of Multidrug Resistance by Lapatinib. Chun-Ling Dai, Amit K. Tiwari, Chungpu Wu, Xiao-Dong Su, Dong-Geng Liu, Yan Huang, Yong-Ju Liang, Li-Ming Chen, Cheng-Jun Shi, Charles Ashby Jr., Zhe-Sheng Chen, Syresh V. Ambudkar, Jian-Ye Zhang, Robert W. Robey, Susan E. Bates, and Li-wu Fu. **Oral presentation** at 5th North American ABC workshop. Sept. 24-26, 2008, NCI-Frederick, Maryland.

36.Differential Effects of the EGFR Tyrosine Kinase Inhibitor AG1478 on the Function of ABCB1 and ABCG2. Zhi Shi, Amit Tiwari, Smitaben Parmar, Suneet Shukla, Robert W. Robey, In-Wha Kim, Susan E. Bates, Qiu-Sheng Si, Curtis S. Goldblatt, Ioana Abraham, Nick Shao,Yang-Min Chen, Annie Zhang, Li-Wu Fu, Suresh V. Ambudkar, Zhe-Sheng Chen. 99th American Association for Cancer Research (AACR), April 12~16, 2008, San Diego, CA

35.Reversal of ABCB1- and ABCG2-mediated MDR by erlotinib (tarceva, OSI-774). Zhi Shi, Xing-Xiang Peng, In-Wha Kim, Suneet Shukla, Qiu-Sheng Si, Robert W. Robey, Susan E. Bates, Sirong Wang, Christine Chim, Tong Shen, Charles R. Ashby, Jr, Li-Wu Fu, Suresh V. Ambudkar, Zhe-Sheng Chen 99th American Association for Cancer Research (AACR), April 12~16, 2008, San Diego, CA

**2007**

34.Multidrug Resistance and Its Reversal. Zhe-Sheng (Jason) Chen, Zhi Shi, Xing-Xiang Peng, In-Wha Kim, Suneet Shukla, Sandeep Jain, Qiu-Sheng Si, Robert W. Robey, Li-Wu Fu, Diaa Youssef, Susan E. Bates, Suresh V. Ambudkar, Khalid El Sayed.**Invited speaker** **(lecture, co-chair)** at 12th World Congress on Advances in Oncology and 10th International Symposium on Molecular Medicine, 11-13 October, 2007, Creta Maris, Hersonissos, Crete, Greece

33.Erlotinib (Tarceva, OSI-774) Antagonizes ABCB1 (P-glycoprotein)- and ABCG2-mediated Drug Resistance. Zhi Shi, Xing-Xiang Peng, In-Wha Kim, Suneet Shukla, Qiu-Sheng Si, Robert W. Robey, Susan E. Bates, Tong Shen, Charles R. Ashby, Jr, Li-Wu Fu, Suresh V. Ambudkar, Zhe-Sheng Chen, The 4th North American ABC workshop, Oct 4~5, 2007, Washington D.C.

32.Development of Sipholane Triterpenes as Modulators of Multidrug Resistance in Cancer. Tong

 Shen, Amit Tiwari, Zhi Shi, Ioana Abraham, Xing-Xiang Peng, In-Wha Kim, Sandeep Jain,

 Charles Ashby, Li-Wu Fu, Diaa Youssef, Khalid El Sayed, Suresh V. Ambudkar, Zhe-Sheng

 Chen. **Oral presentation** at the 4th North American ABC workshop, Oct 4~5, 2007, Washington

 D.C.

31.Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine**.** Amit Tiwari, Xing-Xiang Peng, Zhi Shi, Vijaya L.Damaraju, Xiao-Cong Huang, Gary D. Kruh, Hsiang-Chun Wu, Ying Zhou, Liwu Fu, Carol E. Cass, Zhe-Sheng Chen. **Oral presentation** at the 4th North American ABC workshop, Oct 4~5, 2007, Washington D.C.

30.Sipholenal A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein-mediated multidrug resistance in cancer cells. Zh Shi, Sandeep Jain, In-Wha Kim, Xing-Xiang Peng, Ioana Abraham, Li-Wu Fu, Diaa T. A., Youssef, Khalid El Sayed., Suresh V. Ambudkar, and Zhe-Sheng Chen. 98th Annual Meeting American Association for Cancer Research April 14~18., 2007, Los Angeles, CA

29.Characterization of chronic myeloid leukemia cell lines with acquired drug resistance to 6-MP and imatinib. Xing-Xiang Peng, Zhi-Shi, Xiaocong Huang, Gary D. Kruh., Hsian-Chun Wu., Smitaben Parmar., Ying Zhou, Ioana Abraham., and Zhe-Sheng Chen. 98th Annual Meeting American Association for Cancer Research April 14~18., 2007, Los Angeles, CA

28.Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleotide analogs and

 epothilone B. Elizabeth A. Hopper-Borge, Xiu Xu, Zhe-Sheng Chen, Gary Kruh. 98th Annual

 Meeting American Association for Cancer Research April 14~18., 2007, Los Angeles, CA

**200**6

27. Characterization of a human T cell with acquired drug resistance to 6-mercaptopurine.

Xing-Xiang Peng, Ying Zhou, Vijaya L. Damaraju, Carol E. Cass, Gary D. Kruh, Zhe-Sheng Chen. 97th Annual Meeting American Association for Cancer Research. April 1-5, 2006, Washington D.C.

**2005**

26. Interacting binding sites in Human Multidrug Resistance Protein 8 (MRP8, ABCC11)

Zhe-Sheng Chen, Yanping Guo, Martin G. Belinsky, Elena Kotova, and Gary D. Kruh. 96th Annual Meeting American Association for Cancer Research. April16-20, 2005, Anaheim, Orange County, CA.

25.Analysis of the in vivo functions of Mrp3 using knockout mice

Martin G. Belinsky, Paul A. Dawson, Irina Shchaveleva, Lisa I. Nain, Renxue Wang, Victor Ling, Zhe-Sheng Chen, Alex Grinberg, Heiner Westphal, Andres Klein-Szanto, Anthony Lerro, and Gary D. Kruh. 96th Annual Meeting American Association for Cancer Research. April16-20, 2005, Anaheim, Orange County, CA.

**2004**

24. Transport properties of human multidrug resistance protein 8 (MRP8, ABCC11), A new ABC

Transporter. Zhe-Sheng Chen. **Invited speaker** at Queens University, August 5, 2004, Kingston, Canada (Committee chair: Professor Susan Cole, the discover of MRP1)

23. Functional Studies on multidrug resistance protein 8 (MRP8, ABCC11)

Zhe-Sheng Chen. **Invited speaker** at Shantou University, June 27, 2004, Shantou, Guangdong, China

22.Multidrug resistance proteins (MRPs): Drug Resistance and Substrate Specificity

Zhe-Sheng Chen. **Invited speaker** at Cancer Center, Sun Yat-Sen University, June 22, 2004, Guangzhou, China

21.Functional Studies on multidrug resistance protein 8 (MRP8, ABCC11), A new ABC transporter

 Zhe-Sheng Chen. **Invited speaker** at St. John’s University, April 6, 2004, Jamaica, NY.

20. Multidrug resistance proteins (MRPs):Drug resistance, Substrate specificity and regulation Zhe-

Sheng Chen. **Invited speaker** at The University of Louisiana at Monroe. March 9, 2004, Monroe, LA.

19.Transport of Amphipathic Anions by Human Resistance Protein 8 (MRP8, ABCC11). Zhe-

 Sheng Chen, Yanping Guo, Martin G. Belinsky, and Gary D. Kruh. 95th Annual Meeting

 American Association for Cancer Research. March 27-31, 2004, Orlando, FL.

18. Analysis of the contribution of mrp3 to in vivo chemosensitivity using knock out mice

Martin G. Belinsky, Irina Shchaveleva, Zhe-Sheng Chen, Alan C. Sartorelli and Gary D. Kruh Annual Meeting American Association for Cancer Research. March 27-31, 2004, Orlando, FL. (**Minisymposium)**

**2003**

17.Transport of MTX and 17-Estradiol 17-( -D-glucuronide) by ABCG2 (BCRP/MXR) : Effects

of acquired mutations at amino acid position 482 and polyglutamylation on MTX transport

Zhe-Sheng Chen, Robert W. Robey, Martin G. Belinsky, Irina Shchaveleva, Xaio-Qin Ren, Yoshikazu Sugimoto, Douglas D. Ross, Susan E. Bates, and Gary D. Kruh 94th Annual Meeting American Association for Cancer Research. July 11-14, 2003, Washington DC.

16.Characterization of the Transport Properties of Multidrug Resistance Protein 7 (MRP7,

ABCC10) Zhe-Sheng Chen, Elizabeth Hopper-Borge, Martin G. Belinsky, Irena Shehaveleva, and Gary D. Kruh. 94th Annual Meeting American Association for Cancer Research. July 11-14, 2003, Washington DC. (**Scholar-in-training award’s abstract**)

15. Transport of MTX and 17-Estradiol 17-( -D-glucuronide) by ABCG2 (BCRP/MXR):

 Effects of acquired mutations at amino acid position 482 and polyglutamylation on MTX

 Transport Zhe-Sheng Chen, Robert W. Robey, Martin G. Belinsky, Irina Shchaveleva, Xaio-Qin

 Ren, Yoshikazu Sugimoto, Douglas D. Ross, Susan E. Bates, and Gary D. Kruh

4th FEBS Advanced Lecture Course “ATP-Binding Cassette Proteins: From genetic disease to multidrug resistance”. March 1-9, 2003, Gosau, Austria. (**Plenary Talks**)

**2002**

14. Analysis of Methotrexate and folate transport by MRP4 (ABCC4): MRP4 is component of the

methotrexate efflux system

Zhe-Sheng Chen, Kun Lee, Susan Walther, Rebecca Blanchand-Raftogianis, Michihiko

Kuwano, Hao Zeng and Gary D. Kruh. 93 rd Annual Meeting American Association for Cancer Research. April 6-10, 2002, San Francisco, CA.

**2001**

13.Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by MRP4: Resistance to

 anti-cancer purine analogs. Zhe-Sheng Chen, Kun Lee, and Gary D. Kruh

AACR-NCI-EORTC international conference: Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Oct.29-Nov.2, 2001, Miami Beach, Florida.

12. Transport of Methotrexate and Folates by MRP3 and MRP1: Effect of polyglutamylation on

methotrexate transport. Hao Zeng, Zhe-Sheng Chen, Philip A.Rea, and Gary D. Kruh

92nd Annual Meeting American Association for Cancer Research. March 24-28, 2001, New Orleans, LA.

**1999**

11. Human cMOAT and multidrug resistance

Zhe-Sheng Chen **Invited speaker** in Laboratory of cell biology, Division of Basic Sciences, NCI, NIH, November 16, 1999, Washington DC.

10. Effect of multidrug resistance reversing agents on the transporting activity of human canalicular

multispecific organic anion transporter (cMOAT)

Chen, Z.S., Kawabe, T., Ono, M., Sumizawa, T., Furukawa,T., Uchiumi, T., Wada, M., Kuwano, M., and Akiyama, S.AACR-NCI-EORTC meeting. November 16-19, 1999, Washington, DC.

9. An active efflux system for anticancer drugs and heavy metals in cisplatin-resistant KCP-4 cells

Chen, Z.S., Mutoh, M., Sumizawa, T., Furukawa,T., Tani, A., Kuwano, M., and Akiyama, S.

90th Annual Meeting American Association for Cancer Research. April, 1999, Philadelphia, PA.

8. Transfection of human cMOAT/MRP2 cDNA induces altered sensitivity to anticancer agents

and membrane transport of glutathione conjugates

Kawabe, T., Wada, M., Nakamura, T., Uchiumi, T., Ono, M., Chen, Z.S., Akiyama, S., and Kuwano, M.n 90th Annual Meeting American Association for Cancer Research. April, 1999, Philadelphia, PA. **(Young Investigator award's abstract)**

7. LRP is involved in multiple drug resistance.

Kitazono, M., Sumizawa, T., Takebayashi, Y., Tani, A., Chen, Z.S., Furukawa, T., Aikou, T., Akiyama, S. 90th Annual Meeting American Association for Cancer Research. April, 1999, Philadelphia, PA. **(Young Investigator award's abstract)**

**1998**

6. An efflux pump for heavy metals different from MRP and cMOAT in cisplatin-resistant human

KB carcinoma cells. Chen, Z.S., Sumizawa, T., Furukawa, T., Haraguchi, M., Tani, A., and

Akiyama, S. 5th Hong Kong International Cancer Congress. November 8-11, 1998. Hong Kong,

China **(Young Investigator award's abstract) (Speech)**

5. Cisplatin Resistance.

Akiyama, S., Chen, Z.S., Sumizawa, T., Furukawa, T., Kuwano, M. Symposium. 5th Central European Lung Cancer Conference. September 13-16, 1998, Prague, Czech Republic.

4. Induction of MRP and LRP by differentiating agent, sodium butyrate. Kitazono, Takebayashi,

 Y., Nagayama, S., Tani, A., Chen, Z.S., Furukawa, T., M., Sumizawa, T., Takao, S., Aikou, T.,

 and Akiyama, S. The 89th Annual Meeting American Association for Cancer Research, April,

 1998, New Orleans, LA.

3. ABC transporters and Camptothecin drug resistance.

Chen, Z. S. **Invited speaker** at Shantou University, March 20, 1998, Shantou, Guangdong, China

**1997**

2. Reversal of MRP-associated drug resistance by the pyridine analog, PAK-104P

Chuman, Y., Chen, Z.S., Sumizawa, T., Seto, K., Furukawa, T., Haraguchi, M., Tani, A., Shudo, N., Yamada, K., Akiyama, S., and Aikou, T. The 88th Annual Meeting American Association for Cancer Research. April, 1997, San Diego, CA.

1. The role of glutathione in cisplatin resistant KCP-4 cells.

Chen, Z.S., Mutoh, M., Sumizawa, T., Chuman, Y., Furukawa, T., Haraguchi, M., Tani, A., Handa, K., Saijo, N., and Akiyama, S. The 88th Annual Meeting American Association for Cancer Research, April, 1997, San Diego, CA.

**Medium Exposure**:

1. CCTV International Health Channel（央视国际健康养生频道）， May 18，2012， “About Cancer Prevention and Treament”抗癌话题讲座—陈哲生教授
2. Interviewed by Journal of Family Pharmacy （家庭药师），June 1st, 2011, “Drug Resistance in Cancer”（肿瘤也耐药）
3. AACR medium，April， 2011， Telephone interview， “About discovery of Viagra as enhancer of cancer treatment”
4. Lianping TV Station （连平电视台）， April 1990，“How to identify the toxic Swellfish from non-toxic one”（如何辨别河豚鱼有毒）